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Abstract 
Background: Recent international guidelines call for universal use of triple-drug antiretroviral 
therapy (ART) in HIV-infected women during pregnancy and postpartum. There are however 
concerns regarding potentially high levels of non-adherence and/or loss to follow-up (LTF) that 
may attenuate the benefits of ART for HIV transmission and maternal health. We investigated 
missed visits and LTF among women initiating ART during pregnancy in Cape Town, South 
Africa. 
Methodology: A retrospective cohort study was conducted of women starting ART between 
January 2011 and September 2012, at a large primary care antenatal clinic. Eligible women were 
identified in prevention of mother-to-child transmission (PMTCT) services based on CD4 ≤350 
cells/µl, and women initiated a regimen of tenofovir, lamivudine and efavirenz. Women eligible 
for ART were either referred to general adult ART services nearby (January-December 2011) or 
received ART integrated into ANC services (January-September 2012). Outcomes were 
measured up to six months postpartum: (i) LTF (no attendance within 56 days of a scheduled 
visit) and (ii) missed visit (returning to care 14-56 days late for a scheduled visit). 
Results: A total of 358 women (median age, 28 years; median gestational age at initiation, 26 
weeks) initiated ART during pregnancy. By six months postpartum 24% of women (n=86) had 
missed at least one visit and 32% (n=115) were LTF. Overall, 49% of women had either missed 
a visit or were LTF by six months postpartum.  LTF was more than twice as frequent postpartum 
compared to in the antenatal period (6.2 vs 2.4 per 100 woman-months, respectively; p=0.0004). 
In a proportional hazards model, later gestational age at initiation (HR: 1.04; 95% CI: 1.00-1.07; 
p=0.030) and being newly diagnosed with HIV (HR: 1.57; 95% CI: 1.07-2.33; p=0.022) were 
significant predictors of LTF after adjusting for patient age, starting CD4 cell count and site of 
ART initiation. Site of ART initiation was not a significant predictor of LTF in this analysis. 
Conclusions: These results demonstrate that missed visits and LTF occur frequently among 
HIV-infected women initiating ART during pregnancy, particularly post-delivery. Further 
research is required to understand reasons for non-adherence and LTF and the implications 
thereof in the context of pregnancy. Women newly diagnosed with HIV and those presenting at 
later gestational ages may be particularly vulnerable and there is an urgent need for interventions 
to promote retention among all HIV-infected women during pregnancy and after delivery. 
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A. PROTOCOL  
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1 Protocol Synopsis 
In South Africa, 30% of all women presenting for antenatal care (ANC) are HIV-infected. 
Antiretroviral therapy (ART) is known to be a highly effective method of preventing mother-to-
child transmission (PMTCT) of HIV and promoting maternal health, however adequate 
adherence to ART throughout the antenatal and breastfeeding period is needed to ensure women 
maintain viral suppression, and to maximise the success of the PMTCT programme. Poor 
retention is a major barrier to ART adherence and loss to follow-up (LTF) is common among 
pregnant women on ART [1–3]. 
For pregnant HIV-infected women, the shift from formula feeding to exclusive breastfeeding has 
heightened the importance of continued ART adherence after delivery. In 2011 the South African 
National Department of Health began promoting exclusive breastfeeding, regardless of a 
woman’s HIV status. More recently, the Western Cape Department of Health adopted a policy of 
universal initiation of lifelong ART for all HIV-infected pregnant women. Both of these policies 
rely on retaining HIV-infected women in care during pregnancy and postpartum. 
The overall aim of the proposed research is to describe retention in maternal ART services 
during pregnancy and after delivery, and to investigate possible predictors of retention in this 
population. The analysis is part of a study in Gugulethu, Cape Town that investigated the linkage 
of HIV-infected ART eligible pregnant women to ART services at either a nearby general ART 
clinic, or an integrated ART service within the antenatal clinic. The key finding of the parent 
study was that the proportion of women initiating ART before delivery was greatest, and the 
delays to ART initiation minimized, in a model of care that integrated ART into ANC [4]. 
Retention of women on ART following initiation during pregnancy was not addressed in the 
parent study. 
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The proposed study will investigate retention in ART services from ART initiation up to six 
months postpartum among women who initiated ART during pregnancy. The primary objective 
is to describe the timing of LTF in ART care during pregnancy and after delivery. The secondary 
objective is to investigate possible predictors of retention in maternal ART services. The primary 
outcome of the proposed study will be maternal retention in ART services up to six months post-
delivery. The study population will be assembled retrospectively using routine medical service 
records, and will include all women attending ANC at Gugulethu Midwife Obstetric Unit (MOU) 
who initiated ART during pregnancy between January 2011 and September 2012. Women who 
initiated ART after delivery and those who presented for ANC already on ART will be excluded.  
With the movement towards initiation of ART in all HIV-infected pregnant women, the numbers 
of women initiating ART during pregnancy are rapidly increasing. The proposed research will 
contribute to the growing knowledge base on retention in ART services during pregnancy and 
after delivery, and inform future research to promote ART retention in the context of pregnancy. 
2 Introduction 
2.1 Background 
Mother-to-child transmission (MTCT) of HIV is an important contributor to new childhood HIV 
infections. It is estimated that globally, 1.4 million HIV-infected women give birth each year and 
that 91% of pregnant women living with HIV are in sub-Saharan Africa (SSA) [5]. In 2010, 30% 
of pregnant women attending antenatal care (ANC) services in South Africa were HIV-infected 
[6]. In 2011 it was estimated that 70% of maternal deaths and 50% of under-5 mortality in South 
Africa was associated with HIV [6,7].  
Antiretroviral therapy (ART) has become widely accepted as a safe and efficacious method of 
prevention of mother-to-child transmission (PMTCT) of HIV. In 2010, the South African 
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National Department of Health revised their clinical guidelines for PMTCT to align with recent 
World Health Organisation (WHO) recommendations [5]. Lifelong ART was recommended for 
pregnant HIV-infected women with a CD4 cell count of 350 cells/µl or less, or with WHO 
clinical stage III / IV disease. Women who were not ART eligible were started on  
azidothymidine (AZT) at 14 weeks gestation, received single-dose nevirapine (sdNVP) and three 
hourly AZT intrapartum, and postpartum received a single dose of tenofovir (TDF) and 
emtracitabine (FTC) [8]. 
The use of ART in PMTCT programmes has been rapidly scaled-up around the world resulting 
in large reductions in MTCT rates [7]. Rates of MTCT in Europe and North America are now 
below 1% [9]. In SSA the number of new paediatric HIV infections dropped by 24% from 2009 
to 2011 [7]. In South Africa the decrease for the same period was between 40 and 59% [7]. In 
2010,  a national survey of infant HIV status in South Africa found MTCT rates to be between 3 
and 5% [10]. In 2011, South Africa’s PMTCT coverage reached 75%, well above the overall 
figure for SSA of 59% [6,7]. Coverage of maternal ART is influenced by the strength of linkage 
to ART care from the antenatal services. Among women who do link to care and initiate ART, 
adherence is often suboptimal. A recent meta-analysis investigating adherence to antiretroviral 
therapy during and after pregnancy in different income settings, reported a pooled estimate of 
74% of pregnant women having above 80% ART adherence [11].  
In order for ART to be successful in preventing MTCT, maternal viral suppression must be 
maintained from as early as possible in pregnancy, during delivery and throughout the period of 
breastfeeding [11,12]. HIV-infected mothers need to firstly, link successfully to PMTCT services 
and secondly, be retained in care and maintain adequate adherence levels throughout the 
pregnancy and postpartum breastfeeding period [12]. Poor adherence leads not only to increased 
risk of maternal disease progression and MTCT, but may also result in drug resistance [13]. 
There is growing recognition that loss to follow-up (LTF) from ART services is a major barrier 
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to adherence [14] and several studies have suggested that LTF is a particular concern among 
pregnant women on ART, both during pregnancy and after delivery [2,3,15,16]. 
Breastfeeding and HIV transmission 
New paediatric HIV infections are usually the result of MTCT that takes place either in utero, 
intra-partum or postpartum during breastfeeding. In SSA, breastfeeding is thought to account for 
40% of new paediatric HIV infections [17]. Reducing breastfeeding may remove the risk of 
MTCT but it has other significant negative impacts on child survival [18,19]. In response to 
growing evidence South Africa started promoting exclusive breastfeeding for HIV-positive 
mothers in 2011, replacing previous recommendations of formula feeding. With adequate 
adherence, maternal ART through pregnancy and breastfeeding is able to provide protection 
from MTCT and allow HIV exposed infants the widely known benefits of breastfeeding [11,17]. 
Women who are not retained and/or adherent to treatment will not be virally suppressed and 
consequently the risk of MTCT is increased. In order to achieve optimal health outcomes in 
HIV-exposed infants, a focus on maternal ART adherence and retention is needed in parallel 
with the promotion of exclusive breastfeeding. 
Timing of attrition 
There are multiple points in the PMTCT cascade where women are lost to care. Attrition 
between determination of ART eligibility and initiation of ART has been widely studied [20]. 
Services offering ART are often separated from ANC services. This has resulted in large losses 
between women being identified as HIV-positive during ANC, and presentation at an ART 
service. Stinson et al. [21] analysed data from four antenatal clinics in Cape Town in 2005. They 
found that 51% of ART eligible women had initiated ART before delivery. A further 27% 
received another form of PMTCT [21]. In 2010, at a single facility in Cape Town, it was found 
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that only 21% of ART eligible pregnant women were screened and initiated ART after referral to 
ART services from ANC during a pre-intervention study phase [4]. 
Following ART initiation, LTF appears to increase with increasing time on treatment. Studies 
have shown in general adult ART services that the proportion of patients remaining in care 
decreases over time while rates of LTF increase [20]. Some literature suggests that pregnant 
women may be at a higher risk of LTF than non-pregnant women and men [1,3,15]. There is also 
evidence to suggest that maternal ART adherence is higher during pregnancy than after delivery 
[11]. In contrast, an analysis of data from general ART services in seven countries in SSA from 
2003-2006, found overall retention to be 85% and found no difference in ART retention rates 
between pregnant women, non-pregnant women and men [23].  
Barriers identified to adherence and retention 
Barriers to adherence and retention in ART services for PMTCT have been explored in many 
studies. A systematic review of adherence to ART during and after pregnancy identified 
physical, economic and emotional stresses, depression (particularly postpartum), substance use 
as well as medication frequency of the ART regimen as barriers to adequate ART adherence 
[11]. Economic concerns, stigma and partner related challenges have been highlighted as reasons 
for poor retention and adherence in SSA [24–27]. Wang et al. found that pregnant women with 
lower baseline CD4 cell counts were at high risk of LTF in the six months following ART 
initiation [3]. Younger age was also associated with higher rates of LTF in this study [3]. Toro et 
al. found poor retention to be associated with higher baseline WHO clinical stage, but not with 
CD4 cell count [23]. Service-related factors such as accessibility and quality of care have also 
been recognized as barriers to adherence and retention during pregnancy and postpartum [26,28–
30]. 
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2.2 Background to the proposed dissertation 
In January 2012, an integrated ANC/ART service was introduced to a large primary care 
antenatal clinic in Gugulethu, Cape Town. Prior to this, all women found eligible for ART during 
ANC were referred to nearby general ART services to start ART. The uptake of ART during 
pregnancy in this clinic has been presented by the parent study [4], in which women were 
followed retrospectively through routine medical records from the time of referral from the ANC 
clinic until ART initiation. Retention in care following successful ART initiation during 
pregnancy was not evaluated. 
The proposed research aims to explore retention in this population of women who have initiated 
ART during pregnancy in both the antenatal period and up to six months postpartum. We will 
investigate socio-demographic, obstetric, clinical and service characteristics, in particular the site 
of ART initiation, as possible predictors of retention.  
2.3 Study rationale 
We know that ART is highly effective at protecting against MTCT and promoting maternal 
health, however vertical transmission remains the main contributor to new childhood HIV-
infections worldwide, even in settings with reasonable ART coverage. Poor adherence and/or 
LTF heighten the risk of MTCT and there is growing evidence that poor adherence and/or LTF 
from ART services is common during pregnancy and postpartum [2,11,31]. 
There are limited data investigating retention in ART services among pregnant and, in particular 
postpartum women. Studies assessing overall retention in ART services have suggested that 
pregnant women are particularly vulnerable to LTF [3,15,16]. The existing literature points to a 
higher risk of LTF and non-adherence in the postpartum period [2,11]. In order to ensure that 
governments, health care providers and patients are well equipped for these changes, it is 
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increasingly important that we understand the challenges of retention in ART services during 
pregnancy and postpartum. 
There are on-going investigations into interventions to reduce delays in ART initiation during 
pregnancy and improve maternal ART uptake. It is important to understand the impact of more 
rapid initiation and increased uptake of ART on retention in ART services. We know that the 
uptake of ART during pregnancy is significantly lower when women are referred to general ART 
services compared to integrated ART services [28,29]. This may indicate that many women do 
not successfully navigate the many barriers to ART initiation in the absence of optimal provider 
support. Little is known about retention in ART services beyond treatment initiation during 
pregnancy. 
 
3 Study aims and objectives 
3.1 Study aim 
The overall aim of this dissertation is to investigate retention in ART care during pregnancy and 
postpartum among women initiating ART during pregnancy. 
3.2 Objectives 
1. To describe the timing of LTF from ART services, pre- and post-delivery, from the time 
of ART initiation during pregnancy, through to six months postpartum.  
2. To investigate socio-demographic, obstetric, clinical and service characteristics, in 
particular the site of ART initiation, as possible predictors of retention in the ART service 




The study hypothesis is that retention will be higher during the antenatal period than postpartum. 
Within that, women initiating ART under an integrated model of care are expected to have 
higher rates of retention during the antenatal period compared to women referred out for ART.  
 
4 Methods 
4.1 Study Design 
The proposed research will take the form of a retrospective cohort study of HIV-infected 
pregnant women attending ANC at the Gugulethu Midwife Obstetric Unit (MOU) and initiating 
ART during pregnancy.  
4.2 Study population and sampling 
All HIV-infected women who initiated ART at Hannan Crusaid Treatment Centre (HCTC) or the 
Gugulethu MOU ART service during their antenatal care at Gugulethu MOU between January 
2011 and September 2012 will be included. The cohort will be assembled by review of patient 
folders of all women booking for ANC between November 2010 and September 2012 (allowing 
for a delay between booking for ANC and initiating ART). There will be no direct contact with 
any patients for this research. The study schema is shown in Figure A-1. The grey shaded areas 
represent the proposed dissertation within the parent study [4]. 
Exclusion Criteria 
Participants for whom there is no record of ART initiation at Gugulethu MOU or HCTC will be 
excluded from the analysis. Women who only initiated ART after delivery and women already 
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4.3 Study location 
The study will take place at the Gugulethu MOU and HCTC in Cape Town, South Africa. The 
Gugulethu MOU provides basic ANC and delivery services for a wide catchment area including 
Philippi, Nyanga, Lower Crossroads, Heideveld and Gugulethu. Women from surrounding areas 
and from the Eastern Cape are also known to receive care at this facility [32]. General ART 
services have been provided at HCTC since 2003.  
The two facilities are situated on the same premises but function independently. The integrated 
ART services introduced to the MOU in January 2012 fall under HCTC’s administration. 
Approximately 5000 women book for ANC at Gugulethu MOU each year. In 2011, 
approximately 28% of women booking for ANC were HIV-infected [4]. 
In both ART services, pregnant HIV-infected women who were eligible for ART were started on 
a combination of one non-nucleoside reverse transcriptase inhibitor and two nucleoside reverse 
transcriptase inhibitors [8] and ART eligibility was based on having a CD4 cell count of ≤350 
cells/µl or WHO clinical stage III or IV. Women usually received a 30 day supply of ART for 
the first four months on treatment and thereafter received a 30-60 day supply at the clinician’s 
discretion. Follow up visits were scheduled on a 28 or 56 day cycle depending on the quantity of 
ART supplied.  
4.4 Data collection 
Data will be collected retrospectively from routine medical records. Existing data from ongoing 
operations research at HCTC will also be used. Data will be abstracted by a trained research 
assistant using two structured data abstraction forms. The first form (Appendix A) will collect 
baseline data on the period from referral to initiation of ART. The second form (Appendix B1 & 
B2) will collect data from ART initiation through to six months postpartum. 
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Where outcome data from the record review are missing, the National Health Laboratory Service 
(NHLS) database will be searched in attempt to complete the missing data. Delivery dates will be 
crucial to obtaining estimates of retention in the antenatal and postpartum periods. If no delivery 
date is found in the medical records or on the NHLS database, the gestational age, routinely 
recorded in the Gugulethu MOU, will be used. It will be assumed that delivery occurred at 40 
weeks gestation. 
Table A-1 displays a list of all variables to be collected for this analysis. Dates of all attended 
visits as well as the quantity of ART dispensed will be collected in the ART follow up form 
(Appendix B2). The expected visit date will be determined using the quantity of ART dispensed 
at the last attended visit.  
Table A-1: Variable list 
Variables Type
Age at ART initiation (years) Continuous - numerical
Parity Continuous - numerical
Level of education Categorical  - binary (primary/secondary) 
Employment status Categorical  - binary (employed/unemployed) 
Time of HIV diagnosis Categorical  - binary (new/known positive) 
Disclosure status Categorical  - binary (disclosed/not disclosed) 
Relationship status Categorical  - binary (in a relationship/not in a relationship) 
WHO stage at screening Categorical  - binary (I or II/ II or IV ) 
CD4 at screening (cells/µl) Continuous - numerical
Gestational age at ART initiation (weeks) Continuous - numerical
Site of ART initiation Categorical  - binary (integrated ANC/ART/general ART)
Pregnancy status Categorical  - binary (antenatal/postpartum) 
Definition of outcome variables 
In the literature there are varying definitions of LTF. Studies focusing on retention in general 
ART services define LTF as three to six months with no visit attendance. In the proposed study 
population most women have ART visits scheduled every 28 or 56 days. In previous studies of 
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LTF on ART in the context of PMTCT, a one or two month window for attendance from the last 
scheduled visit has been used to define LTF [2,31,33]. 
 In the proposed study the outcomes will be defined as follows: 
1. Loss to follow-up (LTF)  
Missed a scheduled ART visit and there is no evidence of clinic attendance for at least 56 
days after the scheduled visit date. 
2. Missed visit  
Missed a scheduled ART visit and returned to the clinic between 14 and 56 days of the 
scheduled visit date. 
The study time for each woman will end 56 days following six months after delivery, allowing 
time for outcome definitions to be established for ART visits scheduled up to six months 
postpartum [34]. A woman will be considered retained if she is alive, has not been transferred 
out (TFO) and has not been LTF by the end of the study period.  
Study time will commence on the date of ART initiation and censoring will occur in the 
following instances: 
1. The end of the study period for women retained 
2. Documented transfer out 
3. Documented maternal death 
 
4.5 Potential limitations 
The data for this dissertation will be gathered retrospectively from routine service medical 
records. There may be variation in the quality and content of information recorded in these 
records.  
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Only records from Gugulethu MOU and HCTC will be reviewed and ART service attendance at 
other facilities will not be reviewed. Outcome definitions will be based only on attendance at the 
two ART initiation sites. Movement to other facilities, or transfer without relevant 
documentation, will result in an overestimation of LTF in this cohort of women. Routinely 
collected programme data which records deaths, TFO and LTF will be used to supplement the 
data collected during the record review. 
Women who were referred out and successfully initiated ART during pregnancy may differ 
systematically from those who ultimately initiated ART in the integrated ANC/ART site. 
Differences in baseline variables collected will be adjusted for however there may be other 
unmeasured differences that could introduce bias or confounding into this analysis. 
4.6 Logistics and time schedule 
Table A- shows the expected time frame for completion of the proposed study. The schedule for 
this dissertation is to submit in February 2014.  
Table A-2: Time schedule for completion of dissertation 
Month Sep’13 Oct’13 Nov’13 Dec’13 Jan’14 Feb’14 
Literature Review     
Data collection and capturing    
   
Data Management     
Data Analysis     
Results    
   
Discussion/Write up      
   
 
4.7 Data management and analysis 
The data for this dissertation are quantitative and will come from review of routine medical 
service records. Completed data abstraction forms will be checked for completeness and quality 
and will be captured into a password-protected Microsoft Access (2010) database. This data will 
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be cleaned where necessary and attempts will be made to complete any missing data by returning 
to the source medical records, routine programme database and NHLS database.  
Data will be exported into STATA 12 (STATA for Windows, version 12, Stata Corp; College 
Station, TX) for analysis. Data will be explored using univariate and bivariate descriptive 
statistics. Median and inter-quartile range (IQR), or means and confidence intervals (CI) will be 
used to describe the continuous covariates depending on their distribution. Binary and 
categorical covariates will be described using frequency distributions. Frequency tables will be 
used to examine proportions of LTF and missed visits overall and in the antenatal and 
postpartum period. The frequency of LTF and missed visits will be compared in the antenatal 
and postpartum periods and between the integrated and referred out groups.  
Kaplan Meier analyses will be used to assess time to LTF overall, during pregnancy and 
postpartum. Analyses will be presented for all participants overall as well as stratified by ART 
initiation site. The log rank test will be used to compare survival curves. Cox proportional 
hazards models will be used to investigate potential predictors of retention overall and in the 
antenatal and postpartum periods. The primary outcome of interest is LTF up to six months 
postpartum and secondary analyses will examine missed visits, and/or other definitions of LTF. 
Covariates will be examined as potential confounders or mediators prior to model building. 
Multivariate models will include all covariates for which there is a significant effect on the 
outcome as well as covariates which, when removed, influence associations of other covariates 
and the outcome. Model diagnostics will be done using standard methods and outputs will be 
expressed as hazard ratios (HR) with 95% CI [35]. 
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5 Ethical considerations 
Ethical review 
Ongoing data collection from routine medical records at HCTC has been approved by the 
University of Cape Town human research ethics committee (UCT-HREC) (REC REF 359/2002, 
updated annually). The optimised linkage study described above was also approved by the UCT-
REC (REC REF 391/2010). The proposed study requires additional data abstraction using 
routine service records at HCTC and the Gugulethu MOU, including the NHLS database.   
Informed consent 
The data for this study will come from retrospective review of routinely collected service data. 
There will be no direct contact with any study participants and informed consent will not be 
obtained. As part of the routine services in this setting, all women screened for ART complete a 
simple informed consent document allowing their anonymous health care information to be used 
in research (per REC REF 359/2002). 
Risks 
This study represents minimal risk research. Because of its retrospective nature, the major risk in 
this research is loss of confidentiality during data collection and management. All data collected 
will be kept strictly confidential but will not be anonymous until all the data has been captured. 
ART service folder numbers will be collected and used as unique participant identifiers. 
Completed data abstraction forms will be stored in a locked filing cabinet.  Once captured, all 
identifiers will be deleted to ensure the final data set is anonymous. 
There is a small risk that confidentiality could be breached during review of routine medical 
records. The person conducting the data abstraction will receive specific training on issues of 
confidentiality. Every effort will be made to ensure confidentiality is maintained.  
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Benefits 
The proposed study holds no direct benefit for any individual patient, however knowledge gained 
in this study may assist in identifying where efforts should be focused to improve ART retention 
both during and after pregnancy. The study will contribute directly to the knowledge base on 
retention in maternal ART services both during pregnancy and after delivery. It will provide 
further understanding of the impact of integrated ART services on retention in ART care. Given 
the high rates of attrition from ART services over time, particularly among pregnant and 
postpartum women, advancing our knowledge of these issues represents a benefit to both health 
services and the populations served by these services. 
Confidentiality 
Data collected will be non-anonymous and confidential until all data has been captured, at which 
point identifiers will be removed. The ART service folder number will be used as a unique 
participant identifier. Additional identifying information such as name, date of birth and 
provincial folder number, may be collected for those women considered LTF. These identifiers 
will be collected for the purpose of searching routine service databases and the NHLS database 
to determine the retention status of the participant. On completion of these searches the 
additional identifiers will be destroyed. All data collected will be stored in locked cabinet at the 
University of Cape Town. 
Use of Information and Publications 
Publication or presentation of the results of this study will be agreed upon in collaboration with 
the study investigators of the parent study. 
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B. LITERATURE REVIEW  
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1 Introduction and objectives of this literature review 
In July 2011, a global plan was launched for the elimination of new human immunodeficiency 
virus (HIV) infections among children by 2015 [1]. According to the latest Global Progress 
Report there were 260 000 children newly infected with HIV globally in 2012, most of these as a 
result of mother-to-child transmission (MTCT). Sub-Saharan Africa (SSA), where 90% of new 
infections occurred, is home to 92% of pregnant women living with HIV [2]. South Africa, 
where 30% of women attending antenatal care (ANC) are HIV-infected, has achieved a 63% 
decline in new HIV-infections in children since 2009, two thirds of the way to the target of 90% 
reduction by 2015 [2].  
Triple-drug antiretroviral therapy (ART) has repeatedly been shown to be a highly effective 
prevention of mother-to-child transmission (PMTCT) intervention and has been incorporated 
into PMTCT policy around the world [3]. South Africa has been providing ART for PMTCT 
since 2004 when National PMTCT guidelines recommended lifelong ART for all pregnant HIV-
positive women with CD4 cell count ≤200 cells/µl; in 2010, this threshold was raised to ≤350 
cells/µl. As of 2013, the South African National PMTCT guidelines now recommend ART, as 
treatment or prophylaxis, for all HIV-infected pregnant and breast feeding women following 
World Health Organization (WHO) guidelines (Table B-1).  
Table B-1: WHO recommended PMTCT interventions [3] 
 CD4 cell count ≤ 350 cells/µl CD4 cell count > 350 cells/µl 
Option A ART for life 
 
AZT prophylaxis starting at 14 weeks gestation.  
sdNVP and AZT/3TC at delivery and for 7 days 
postpartum. 
Option B ART for life Triple ARV prophylaxis from 14 weeks 
gestation until delivery or 1 week after cessation 
of breastfeeding 
Option B+ ART for life ART for life 
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Despite its known efficacy, many barriers exist to the successful implementation of ART for 
PMTCT. ART can only effectively prevent MTCT if women start taking treatment early enough 
in pregnancy and remain in care and adherent throughout the period of exposure [4]. Integrated 
ANC/ART services have bridged some of the barriers to ART initiation during pregnancy and 
have resulted in  improved ART uptake for PMTCT compared to stand alone ART services [5–
7].  The next step is to ensure ART adherence and retention during pregnancy and breastfeeding. 
For women starting lifelong ART there is the added challenge of ongoing retention in care as 
well as ensuring a successful transition from ART during pregnancy into general ART services. 
Existing evidence suggests that loss to follow up (LTF) from PMTCT programmes during 
pregnancy and postpartum may be common [8–10]. LTF is a major contributor to poor 
adherence and a significant barrier to the success of ART for PMTCT. However the factors 
influencing retention and adherence during pregnancy and post-delivery are not yet well 
understood. In the 2013 WHO PMTCT guidelines, adherence and retention to ART during 
pregnancy and after delivery are highlighted as key areas requiring further research [3].  
This dissertation investigates retention in care following ART initiation during pregnancy. It 
explores factors influencing retention in the antenatal and postpartum periods, focusing in 
particular on integrated and non-integrated models of ART initiation for HIV-infected pregnant 
women. To inform this research, the objectives of this literature review are: 
• To describe existing evidence regarding antenatal and postpartum adherence and LTF 
from HIV services following ART initiation during pregnancy. 
• To compare adherence and retention in services where women are referred out for ART 
and where women receive integrated ART care.  
• To identify barriers to retention in ART care and adherence to ART during pregnancy 
and after delivery 
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2 Search methods  
PubMed and Google Scholar were searched using the search terms HIV, antiretroviral treatment, 
pregnancy, retention and integration, as well as their variations (See Box 1). The search was 
restricted to English language publications and data reported from the African continent. Titles 
and abstracts of resulting articles were reviewed and references of included studies and existing 
reviews were searched. All publications available through 28 February 2014 were included in 
this review. 
Publications were included in the review if (i) the population of interest included HIV-infected 
pregnant or postpartum women, and (ii) uptake of ART during pregnancy, maternal retention in 
ART care or adherence to ART during pregnancy was an outcome of the study. Studies of both 
ART for maternal health and ART prophylaxis were included in the review. Publications 
focusing on optimal ARV regimen/drug efficacy, short term ARV prophylaxis (sdNVP, AZT 
prophylaxis), infant treatment or infant outcomes were excluded from this review. The included 
studies are summarised in Table B-2. 
 
Box 1: Search strategy 
HIV: Human immunodeficiency virus, mother-to-child transmission, MTCT, vertical transmission 
Antiretroviral treatment: ART, PMTCT, antiretroviral 
Pregnancy: pregnant, antenatal, antepartum, postnatal, postpartum, maternal 
Retention: follow up, LTF, loss to follow up, attrition, linking to care, adherence, retained, loss to care 
Integration: integrated, referral 
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3 Results 
3.1 The importance of adherence and retention 
Adherence to ART is closely linked to achieving viral suppression [11,12]. In turn, non-
adherence leads to higher levels of viraemia that have been consistently associated with an 
increased risk of MTCT during pregnancy, delivery and breastfeeding [13,14]. The importance 
of adherence to ART is therefore heightened in the context of pregnancy as both the risk of 
MTCT and ongoing maternal health must be considered. Studies on ART for PMTCT specify 
thresholds for adequate adherence between 80-100% [15].  
In order to achieve adequate adherence and ultimately viral suppression, women must regularly 
attend ART services to receive their treatment. Non-retention is a significant barrier to ongoing 
adherence. Treatment interruptions not only result in increased maternal viraemia but have also 
been linked to the development of treatment resistance [16]. In an MTCT setting, this poses a 
threat to maintaining ongoing maternal health and introduces a risk for transmission of drug 
resistant virus to the infant.  
3.2 Retention and adherence following ART initiation during pregnancy 
Pregnant women have repeatedly been shown to be at high risk for non-adherence and poor 
retention in ART services. Studies investigating retention in general adult ART services from 
across SSA have found that pregnant women are at a higher risk of being LTF compared to non-
pregnant women and men [8,10,17,18]. In Gugulethu, Cape Town, Kaplan et al. found that 
pregnant women were significantly more likely to be LTF both pre- and post- treatment initiation 
when compared to non-pregnant women, however mortality was lower among pregnant women 
[17]. Working in other parts of South Africa, Boyles et al. and Wang et al. found a more than 
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three-fold increased hazard of being LTF among pregnant women compared to non-pregnant 
women and men [8,10].   
The literature suggests that among women starting ART during pregnancy, levels of maternal 
ART adherence and/or retention in care vary during the antenatal and postpartum periods. In a 
meta-analysis focusing on adherence to ARVs during pregnancy and postpartum, Nachega et al. 
reported a higher pooled estimate of adequate adherence (defined as >80% adherent) in the 
antenatal period (76%) compared to the postpartum period (53%) [15]. Estimates from Kenya 
and Nigeria suggest that about 80% of women had adequate adherence (defined as >95% 
adherent) to ART during pregnancy [11,19]. In South Africa, Black et al. found that 28% of 
ARV naïve women initiating ART during pregnancy in an integrated ANC/HIV service were 
LTF before six weeks postpartum [20]. Clouse et al. [9] also examined LTF during pregnancy 
and after delivery in South Africa. They reported that 77% of women who initiated ART during 
pregnancy returned for at least one postpartum visit. Of those women who returned, 83% were 
still in care six months after ART initiation [9]. Other studies from South Africa and Kenya have 
found that approximately two thirds of women remain adherent and in care until delivery [21,22] 
and up to 28 days postpartum [23]. 
Definitions of retention, LTF and adherence are not standard, making it difficult to compare 
findings in different settings. Okonji et al. assessed adherence to triple ARV prophylaxis among 
pregnant women in Kenya using pill counts, participant-maintained drug calendars and self-
reported three day and one month adherence [11]. They found that 84% of women had >95% 
adherence over the study period. No significant difference in the level of adherence or viral 
suppression was detected at delivery, 14 and 24 weeks postpartum [11]. At an urban HIV 
treatment centre in Nigeria, 80% of women had >95% adherence to ART during pregnancy 
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based on three day recall [19]. Ayuo et al. measured disengagement from care during pregnancy 
in Kenya and found that overall 32% of women disengaged from care at some time prior to 
delivery [21].  
Overall, the literature suggests multiple challenges to adherence and retention during and after 
pregnancy, and that these issues are more prominent postpartum. Many of the identified barriers 
have been present across both the antenatal and postpartum periods, however much of the 
literature does not extend far past delivery. Available literature does suggest that adherence and 
retention in ART care is worse after delivery than during pregnancy [15,24].  
Referral and successful linkage to HIV care following identification in ANC is a major barrier to 
ART uptake during pregnancy as well as continued retention in care. Several studies have 
recognized the difficulties of successful referral to ART services outside of ANC [25–28]. 
MacPherson et al. investigated referral to ART care among a general adult population in Malawi 
and found that pregnant women were less likely to be referred directly to ART services than non-
pregnant women and men [25]. In a Zimbabwean study investigating referral of ART eligible 
women from PMTCT services in an ANC clinic to a general adult ART clinic, only 65% of 
women who were referred for ART successfully registered for the ART programme. Of these 
only 37% initiated ART and a further 37% were being monitored for ART eligibility. The study 
also found that only 16% of all referrals had been correctly documented at the ANC clinic 
completing the referral [27]. Watson-Jones et al. noted that referral to ART services following 
positive HIV tests during ANC, delivery or postpartum was poor [26]. The study found that 30% 
of health workers did not correctly refer women to ART care and that only 32% of women 
referred had actually been assessed for ART four months following the referral.  
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Few interventions have been investigated to improve ART uptake. Data from Malawi have 
shown that facility based interventions to improve service linkage for ART eligible pregnant 
women are able to improve ART uptake and retention [29]. Retention at six months on ART 
improved from 17% pre-intervention to 65% [29]. In South Africa, a targeted quality 
improvement campaign among health workers improved referral for and uptake of ART by 
eligible pregnant women [30]. Integrated ART services have removed the need for referral to 
stand alone ART services during the antenatal period and have significantly improved ART 
uptake during pregnancy [5,6]. These interventions have resulted in fewer losses between ART 
screening and ART initiation, however after successful ART initiation women must still 
negotiate the barriers to ongoing adherence and retention in care. 
3.3 Barriers to or enablers of retention and adherence during pregnancy/postpartum 
Adherence to ART and retention in ART care is an ongoing challenge for women initiating 
treatment during pregnancy. Stinson & Myer comment on a “triple burden” of firstly dealing 
with pregnancy and motherhood, secondly accepting the HIV diagnosis and thirdly coming to 
terms with the need to start lifelong treatment to protect from MTCT as well as for ongoing 
maternal health [31].  Studies have identified many barriers to ART adherence and to retention in 
ART care including individual-level, socioeconomic and service- related factors.  
Individual-level factors  
Several of the demographic associations with retention in non-pregnant/postpartum adult 
populations have also been documented in pregnant women. For example, younger age is often 
associated with increased risk of LTF and studies of ART use in the antenatal and postpartum 
periods have found that older women were less likely to be lost from care or to have poor 
adherence compared to younger women [9,10,21]. The evidence regarding gestational age and 
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retention is unclear. Earlier gestational age at ART initiation has been shown to be associated 
with increased risk of disengagement from care prior to delivery [21] and there is also evidence 
that late gestational age at presentation for ANC increases the likelihood of  being LTF prior to 
delivery [9]. 
Women’s motivations for using ART during pregnancy may act as an additional barrier to 
adherence and retention. Ngarina et al. found an increasing prevalence of unsuppressed viral load 
with increasing time postpartum among women who had initiated ART during pregnancy in 
Tanzania [24]. Among women with detectable viraemia at 24 months postpartum there was a 
decreased motivation to take ART after delivery and after weaning the infant [24]. The primary 
motivation for taking ART documented in the study was to protect from MTCT. Stigma, 
poverty, daily demands and the need to keep treatment a secret have been highlighted as 
significant barriers to adherence, both in the antenatal and postpartum periods [22,24].  A peer 
mentoring intervention in a PMTCT programme in South Africa led to women reporting better 
social support and reduced depression scores [32]. Women who received the intervention were 
more likely to return for follow up visits [32]. In Nigeria, having a treatment supporter has also 
been shown to improve adherence to PMTCT [19]. 
Among clinical characteristics, disease severity is thought to be a correlate of retention and 
adherence in both general adult populations and among pregnant women. Higher CD4 cell count, 
indicating a better baseline health status, was associated with higher odds of disengaging from 
care in a sample of pregnant women receiving ART for PMTCT in Kenya [21]. Similarly, better 
perceived health was found to be associated with poor ART adherence among postpartum 
women in Tanzania [24]. Pregnant women in general have a better baseline health and higher 
CD4 cell counts at the time of ART initiation than new initiates in the general adult population 
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[8,10,18]. One hypothesis is that healthier individuals are less motivated to take medication for 
their own health with no obvious signs of illness. In the antenatal setting this may be overcome 
by the increased motivation to adhere to treatment to prevent infant HIV infection, however 
when a woman enters the postpartum period her own perceived health may influence her 
motivation to remain in ART care [24].  
Knowledge and understanding of HIV and PMTCT has also been shown to influence retention in 
care. Women in Ghana with poor knowledge of PMTCT were more likely to default in the first 
six months of treatment compared to women with good knowledge of PMTCT [33]. In Kenya, 
women who reported believing that ART was effective were more likely to access ART services 
[34]. Misunderstandings and misconceptions about PMTCT were reported as a major reason for 
non-adherence in rural South Africa [22]. Along with general knowledge about PMTCT and 
HIV, knowledge of the local programme systems is also important. Muchedzi et al. found that 
pregnant women in Zimbabwe who understood the PMTCT/ART referral systems were much 
more likely to successfully access care following referral from ANC [27]. 
Socioeconomic factors 
Relationship status and partner influence on ART adherence and retention during pregnancy and 
postpartum have been widely investigated. Ayuo et al. found that in Kenya, women who were 
married were at a higher risk of LTF than single women [21]. Other studies have found that fear 
of disclosure to a partner as well as limited partner support and trust were significant barriers to 
adherence and retention [35,36]. In general, partner involvement in antenatal care as well as 
PMTCT programmes appears to be low in many parts of SSA and in South Africa in particular. 
A recent review of the literature noted that one of the main barriers to male involvement in 
PMTCT is the perception that antenatal care and PMTCT is an activity only for women [37,38]. 
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This socio-cultural perception results in women navigating the ANC and PMTCT systems 
without partner support. Otieno et al. found that Kenyan women who had discussed referral for 
ART care with their partner were more likely to access care than women who did not [34]. Duff 
et al. examined barriers to ART from a partner perspective by interviewing husbands of women 
enrolled in a PMTCT programme in Uganda [39]. Men reported that they did not feel sufficiently 
involved in the PMTCT process. They identified disclosure and stigma, as well as low levels of 
PMTCT knowledge among men and low partner testing rates, as significant barriers to ART in 
pregnancy [39]. Similar barriers were identified by women and their husbands in Malawi [36]. 
In addition, economic concerns are important barriers to accessing HIV and maternal and child 
health services in most settings. During both the antenatal and postpartum periods, financial 
concerns have been found to hinder ART adherence and retention [24,34,40]. For instance, Duff 
et al. reported that a pregnant woman’s dependence on her partner for financial support was a 
significant barrier to accessing care [40]. Theft of ARVs by relatives and domestic violence have 
also been noted as reasons for poor adherence [22]. 
Service-level factors 
There is growing attention in the literature to the features of health care services that may 
influence ART adherence and/or retention during pregnancy and postpartum. Poor patient-
provider relationships tend to increase the risk of disengagement from care [40]. Lack of trust in 
the health care provider, fear of disclosure and lack of confidentiality have been shown to 
increase the risk of women disengaging from care [27,34,41]. Long waiting times and overall 
dislike of the ART facility have been noted as barriers to adherence and retention [27,34,40]. 
Good health education, counselling and compassion from providers have been reported to 
encouraged attendance of ART services [34,38].  A mixed methods study investigating success 
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of referral to stand alone ART clinics from ANC in Tanzania, noted that ongoing HIV care was 
not covered in HIV education sessions in the ANC clinic [26]. With policies shifting to ART for 
all pregnant and breastfeeding women, the inclusion of information on HIV and postpartum ART 
care in general education sessions will be very important. The physical location, opening hours 
and accessibility of services have also been found to be barriers to ART uptake [38,42,43]. 
Retention in ART care was improved in Kenya by the use of an active defaulter tracing system. 
Active tracing of women who had missed a visit by two or more weeks resulted in 60% of 
PMTCT patients returning to care [43]. 
3.4 Integrated ANC & ART  
Integrating ART services into routine ANC is becoming an important feature of PMTCT 
programmes across Africa. The WHO and South African National PMTCT guidelines now 
recommend immediate ART initiation for all HIV-infected pregnant women. Integrating ART 
services into existing ANC facilities will be required to achieve this rapid initiation in all 
pregnant HIV-infected women.  
Uptake and retention 
Integrated services have been repeatedly shown to significantly increase the uptake of ART prior 
to delivery [5–7]. In a recent report of routine programme data from Malawi, where Option B+ 
was implemented in the second half of 2011, ART uptake among pregnant and breastfeeding 
women increased 748% after one year of B+ implementation [7]. There has however been some 
concern that the rapid initiation of ART facilitated by integrated services may negatively impact 
long term retention and other outcomes. Pre-ART preparation has been a focus of preventing 
poor-adherence and promoting retention [44–46].  Fewer counselling sessions and reduced 
preparation time with rapid ART initiation in pregnancy may have implications for adherence 
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and retention. There are few data available to address this however the few existing studies have 
found similar outcomes among women in integrated and non-integrated services. In 2010, Killam 
et al. found that retention in care at three months on treatment was equivalent among women 
initiating ART in an integrated service (87%) and those referred out to separate ART services 
(91%) [6]. An early report from Malawi showed that retention at 12 months on ART, following 
implementation of option B+, was 77% [7]. This was in line with the national general ART 
retention rates. More recently, Myer et al. found that delays between screening and ART 
initiation, intended to further prepare women for the challenges of ART for PMTCT and for life, 
did not improve outcomes of retention in care at 12 months on treatment or improve levels of 
viral suppression at each ART visit [47].  
Acceptability 
Another concern regarding integrated ART and rapid ART initiation during pregnancy is 
acceptability for both pregnant HIV-infected women as well as the health care providers who are 
required to implement the guidelines. In 2012, a survey from Kenya found satisfaction with 
services to be higher among women attending integrated ART services (79%) compared to 
among women attending standalone ART services (54%) [48]. Another Kenyan study explored 
integrated ART services from a provider perspective [41]. During in-depth interviews, providers 
noted that integration of ART and ANC services meant less time for patients in health facilities 
but also raised concerns about increased provider time with each patient and an increased 
workload. Improved patient-provider relationships, confidentiality and less stigma in an 
integrated service compared to stand alone ART services were thought to improve the uptake of 




Although faster ART initiation as a result of integrated services has been highlighted as a 
concern, it also offers a significant advantage in the context of pregnancy. The literature suggests 
that the optimal time on ART prior to delivery is 8-13 weeks to ensure viral suppression and 
minimize the risk of MTCT [12,23,49,50]. In integrated ART services there are fewer delays 
between being identified as ART eligible and ART initiation. Women therefore start ART earlier 
and have a longer time on ART prior to delivery, improving their chances of reaching viral 
suppression by delivery and maximizing the benefit of ART for PMTCT [5,50–52].  
3.5 Areas for further research 
We know that ART is a very effective intervention for PMTCT, however we also know that 
pregnant and postpartum women are vulnerable to being lost to care. There is a need to better 
understand the challenges around ART that are particular to pregnant and postpartum women. 
Further knowledge on the timing of LTF and  the most vulnerable points on the PMTCT cascade 
will help to inform interventions to improve ART adherence and support retention.  
 
Globally, PMTCT policy is shifting to integrated same day ART initiation within ANC clinics. 
Existing literature suggests that rapid, integrated ART initiation does not negatively impact on 
future retention [6,47], however LTF and adherence remain a concern. Most women who initiate 
ART in an integrated ANC/ART service will ultimately be transferred to general adult ART 
services post-delivery. Successful linkage to care following referral out in the postpartum period 
is required to ensure ongoing retention in care. There are few data investigating linkage to 
ongoing ART care following initiation of lifelong ART in an integrated ART service. Given the 
34 
appreciable challenges of linking to care in the absence of integrated services, there is a need for 
research focusing on postpartum linkage to ongoing ART care.  
 
This literature review underscores the need for additional research into the frequency and timing 
of LTF from ART services following ART initiation. Following from this, the proposed study 
aims to further our knowledge of the rate of LTF in the antenatal and postpartum periods and to 
investigate predictors of LTF both during pregnancy and after delivery. The knowledge 
generated will contribute to the body of literature on ART services for PMTCT and maternal 
health, and aims to inform the development of appropriate and timely interventions to promote 
retention in ART care throughout pregnancy and breastfeeding.  
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Table B-2: Summary of included studies 
In text 
citation Author, year Setting 
Study design 






point Key Findings 
Definition of 
adherence or 
retention outcome (if 
applicable) 
Mixed method studies  











who had been on 












Women with inadequate ART & 
PMTCT knowledge were 3.5 times more 
likely to default ART. Defaulter rate was 
27%. 
Defaulter: missed two 
or more ART 
appointments within 
the previous two 
months 
















usability of an 
SMS support 
group 
Antenatal  SMS support may be an acceptable support option for PMTCT  















ART eligibility assessment was 
suboptimal as was referral to ART 
services. HIV-infected pregnant women 
were significantly less likely to be 
referred directly for ART than non-
pregnant women and men.  
 





















reasons for poor 
adherence 
Antenatal 
61% of women had good adherence and 
there was no difference between the two 
treatment groups. Reasons for poor 
adherence therapy included 
misconceptions/misunderstandings, 
interruptions to routine, ARVs taken by 
relatives, domestic violence, poverty and 
issues relating to disclosure and stigma. 
Good adherence: 




citation Author, year Setting 
Study design 






point Key Findings 
Definition of 
adherence or 
retention outcome (if 
applicable) 





after referral to 
HIV care 
postpartum 







74% of women reported attending the 
referral HIV care site. Barriers to 
attending were lack of money, concern 
about confidentiality and dislike of the 
facility. Women who discussed the 
referral with partner and those who 
believed HAART was effective were 
more likely to access care. Enabling 
were health education, counselling, free 
services and compassion from the 
provider. 
 





















Referral to and 
registration at an 





70% of health workers did refer women 
to HIV care. ANC HIV education did 
not cover ongoing HIV care. Only 32% 
of women followed for 4 months had 
attended and been assessed for ART 
eligibility. Non-attendance was linked to 
fewer ANC visits, nondisclosure, poor 
PMTCT compliance, non-Sukuma 
ethnicity. 
 
Qualitative studies  






already on ART 








Fear of stigma was a reason for non-
adherence in both urban and rural 
women. Importance of partner trust was 
highlighted. Importance of fulfilling 
home responsibilities results in women 
favoring a birth assistant over clinic 
delivery. 
 
























Disclosure, confidentiality, stigma, lack 
of partner support, difficulty accessing 





citation Author, year Setting 
Study design 






point Key Findings 
Definition of 
adherence or 
retention outcome (if 
applicable) 

















Economic concern represented the 
greatest barrier to accessing ART. 
Stigma and non-disclosure to partner, 
clinic waiting times and patient provider 
interactions were also significant 
barriers. 
 














Barriers to ART 





Disclosure and stigma were two major 
obstacles, low male knowledge of 
PMTCT and low testing rate were 
thought to be barriers to women 
accessing treatment. Men felt not 
sufficiently involved in PMTCT. 
 




and focus group 
discussions 
Patients retained 














Reasons for LTF included sex 
inequality, high transport costs to access 
the services, inadequate posttest 
counseling, lack of HIV status 
disclosure, and the location of the ART 
clinic. 
 












load at 24 
months 
postpartum 
ART - for 
own health 




Motivation to take ART decreased after 
delivery and weaning as they no longer 
needed to protect the baby, feeling well 
and feeling hopeless was associated with 
poor adherence. Everyday demands, 
poverty, stigma and need to keep ARVs 
a secret were significant barriers to 
adherence 
 

















women, & health 
care providers 




lifelong ART in 
pregnancy and 




Key challenge to ART initiation: denial 
of HIV status, fear of disclosure, late 
presentation, treatment side effects, 
lifelong commitment to ART. Another 
challenge is dealing with pregnancy, 





citation Author, year Setting 
Study design 






point Key Findings 
Definition of 
adherence or 
retention outcome (if 
applicable) 





























Providers noted that integration meant 
less patient time spent in health 
facilities, increased efficiency and better 
patient-provider relationships. Increased 
confidentially and decreased stigma 
would mean more women will initiate 
ART if services were integrated. Some 
providers concerned that increased visit 
duration would lead to inadvertent 
disclosure. Need to consider impact on 
workload and quality of care. 
 
Quantitative studies  



















89% of women reported taking all 
medication at all visits. 31.9% of women 
disengaged from care. Disengagement 
was associated with decreasing age and 
decreasing gestational age at ART 
initiation 
Disengagement: Early 
- more than 30days 
late but returned prior 
to delivery.  
Late - no visit within 
30 days of delivery 

















27% of women were considered LTF by 
6 weeks postpartum 
 
LTF: Women who did 
not attend the 6 week 
postpartum follow-up 
visit. 





















During the rapid ART initiation 
intervention 97% of eligible women 
started ART and 90.8% started on the 
same day as screening  
 
















Initiating ART while pregnant was an 
independent predictor of LTF in a 
general adult population. Follow up 
period of 4 years 
LTF: no patient 
contact for more than 6 
months. Censored at 
date of last contact 










had an infant 
PCR 








Maximum effect of PMTCT is achieved 
by initiating ART at least 13 weeks prior 
to delivery  
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In text 
citation Author, year Setting 
Study design 






point Key Findings 
Definition of 
adherence or 
retention outcome (if 
applicable) 









ART uptake and 
retention up to 






ART uptake per quarter increased 748% 
after 1 year of B+. Retention at 
12months in facility of initiation was 
77% (excluding those who transferred 
care). Highlight need for integrated care 
and staff training 
Definition of retention 
not stated. 



















testing to 6 







40.5% of ART eligible women 
cumulatively retained through to 6 
months on ART. 20.5% were lost before 
delivery overall, and of those still in care 
after delivery 47.9% were LTF within 6 
months of delivery.  Women booking 
later for ANC were more likely to be 
LTF prior to delivery. Older age was 
protective of LTF after delivery. 
LTF: not returning to 
the clinic within 1 
month after the last 
scheduled visit 








ART - for 
own health 
LTF within 1 




Overall pregnant women had higher 
baseline CD4 cell counts. Different CD4 
categories had no effect on LTF among 
pregnant women. Among non-pregnant 
women and men, lower CD4 cell counts 
were associated with increased risk of 
LTF. Overall, pregnant women were the 
most likely to be LTF. 
LTF: not returning to 
the clinic within 3 
months of the patient’s 
last missed scheduled 
visit 

















After controlling for confounders, HIV 
disclosure and having a treatment 
supporter were associated with good 
adherence. 80% reported good 
adherence 
Adherence: (≥95%) 
using 3 day recall 
 
















HIV testing and 




<50% of known eligible women initiated 
ART. Registration of clients, cost and 
opening hours of services hampered 
uptake. Attendance of more ANC visits 
was associated with attendance at HIV 
care 
 














HIV testing and 




38-88% of known eligible women fail to 
initiate ART. Family focused, integrated 
care seems to improve ART uptake. 
Financial constraints and stigma are 




citation Author, year Setting 
Study design 






point Key Findings 
Definition of 
adherence or 
retention outcome (if 
applicable) 





















72% of women commenced ART before 
delivery. 13% of ART eligible women 
were lost to follow up. Transmission rate 
was 5.1%. No transmission among 
women on ART for >=8weeks prior to 
delivery 
LTF not defined 






















Women in the Mamekhaya intervention 
arm had reduced depression scores and 
improved social support. They were 
more likely to attend follow up visits 
and had a significantly increased HIV 
knowledge score, compared to women 
in the control clinic. 
 

















Crude pre-treatment LTF was 13.2% 
among pregnant women compared to 
6% for non-pregnant women.  At 3 years 
on ART LTF rates were 32% and 13% 
respectively. Pre-treatment mortality 
was significantly lower among pregnant 
women (0.3% vs. 4.7 %)  
On treatment LTF 
defined as not 
attending the clinic for 
12 or more weeks. 











ART - for 
own health 






44.4% of women in the intervention 
cohort initiated ART while pregnant and 
within 60 days of diagnosis, compared 
to 25.3% in the control cohort. 
Integrated ART in ANC can double the 
proportion of eligible women starting 
treatment. Gestational age at initiation 
and retention at 90 days on AR were 
similar in both cohorts. 
Patient retention: the 
number of women 
initiated on treatment 
and still on treatment 
(not LTF, dead, or 
transferred out) in the 
first 90 days of 
treatment. LTF not 
defined. 












eligible for ART 






No differences in demographics found 
between women who did and did not 
initiate ART. Suggest barriers associated 





citation Author, year Setting 
Study design 






point Key Findings 
Definition of 
adherence or 
retention outcome (if 
applicable) 







ART - for 
own health 
Referral to and 




65% of women registered at an ART 
programme but referral was only 
documented for 16% of women. 
Participants who understood the referral 
system and those enrolled in HIV 
support groups were more likely to 
access HIV care. Women living with a 
male partner were less likely to access 
treatment. Barriers to accessing care 
were waiting times and competing life 
priorities. Among those who did access 
care, challenges included waiting times, 
irregular lab testing and transport costs. 
 








referred for ART 















78% of eligible women initiated ART 
before delivery. 75% of women were 
retained at 12months and 91% of 
women were virally suppressed at each 
follow up visit. Delay between screening 
and ART initiation was not associated 
with retention/viral suppression in the 
first year on ART 
LTF: having 60 days 















referred for ART 







With RAP in place, 97% of women 
started ART during pregnancy  





















There was a significant increase in the 
numbers of pregnant women referred for 
ART and the number of women 
initiating ART while pregnant in the 
intervention district. There was no 
improvement noted in the control 
district. A targeted campaign amongst 





citation Author, year Setting 
Study design 






point Key Findings 
Definition of 
adherence or 
retention outcome (if 
applicable) 
[12] Okonji, 2012 Kenya Prospective cohort (n=434) 
HIV-infected 
pregnant women 
still enrolled in 
the KiBS study 









Adherence and duration on ART were 
associated with reaching viral 
suppression. 
Adherence: (≥ 95%) 
by pill count, drug 
calendar and 3 day & 1 
month self report 

















51% of eligible women initiated ART 
before delivery. Early gestational age at 
booking was the strongest predictor of 
initiating ART during delivery 
 




















Women in the integrated model were 
significantly more likely to initiate ART 
antenatally compared to women in the 
distal model. 
 















Retention up to 






Using national data, 17% of women 
were LTF 6 months after ART initiation. 
Women who started ART during 
pregnancy under B+ were 5 times more 
likely to be LTF compared to women 
eligible for ART for their own health 
(CD4<=350/WHO stage 3 or 4). LTF 
was highest among B+ women who 
started ART on the same day as HIV 
diagnosis. There was considerable 
variation of rates of LTF between 
facilities. 
LTF: missed an 
appointment and did 
not return to care for 
more than 60 days. 













prior to delivery, 
duration of ART 
prior to delivery 
Antenatal 
39 women (65%) started ART before 
delivery. Median duration of ART prior 
to delivery was 59 days. Lower CD4 cell 
count was associated with antenatal Art 
initiation and earlier enrolment for ANC 
was associated with longer duration of 




citation Author, year Setting 
Study design 






point Key Findings 
Definition of 
adherence or 
retention outcome (if 
applicable) 









patients in HIV, 














59.4% of all patients and 60.2% of 
PMTCT patients traced returned to the 
clinic. Common barriers given to 
attending care were increased distance to 
the clinic due to moving/traveling, as 
well as the schedule and location of 
employment. 
LTF of HIV patients: 
does not return to the 
clinic within six 
months 
LTF of PMTCT 
patients: does not 
























Median gestation at ART initiation was 
lowest in 2010, meaning longer time on 
ART before delivery. HIV transmission 
was also lowest in 2010. Women on 
ART for <8weeks before delivery were 
more likely to transmit. 37.6% of 
women were LTF within 28 days of 
delivery 
Not clearly defined 












HIV and ANC 
services (n=326) 
Pregnant women 














79% of women in fully integrated clinics 
were very satisfied with the care they 
received, compared to 54% of women in 
non-integrated clinics. HIV-negative 
women did not report any significant 





citation Author, year Setting 
Study design 






point Key Findings 
Definition of 
adherence or 
retention outcome (if 
applicable) 

















Younger age and pregnancy were 
significantly associated with higher rates 
of LTF. 
Patient based LTF: 
Failure to return for a 
scheduled consultation 
or medication pick-up 
within 6 months after 
ART initiation.  
Data-based definition 
LTF: if no information 
was recorded with 
respect to the date of 
the 6-month follow-up 
visit & there was no 
laboratory testing 
(CD4 or HIV RNA 
tests) within 6 months 
of ART initiation. 

















47% of eligible women started ART 
during pregnancy. 43% were alive on 
ART or transferred out at 6months. 
Median delay from screening to 
initiation fell from 2006-2009, and 
proportions of women initiating ART 
and retained at 6months improved 
significantly. Still delays between taking 
CD4 and referral for ART. 
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Abstract 
Background: Recent international guidelines call for universal use of triple-drug antiretroviral 
therapy (ART) in HIV-infected women during pregnancy and postpartum. There are however 
concerns regarding potentially high levels of non-adherence and/or loss to follow-up (LTF) that 
may attenuate the benefits of ART for HIV transmission and maternal health. We investigated 
missed visits and LTF among women initiating ART during pregnancy in Cape Town, South 
Africa. 
 
Methodology: A cohort study was conducted of women starting ART, January 2011-September 
2012, at a large primary care antenatal clinic. Eligible women were identified in PMTCT 
services based on CD4 ≤350 cells/µL, and women initiated a regimen of tenofovir, lamivudine 
and efavirenz. Outcomes were measured up to six months postpartum: (i) LTF (no attendance 
within 56 days of a scheduled visit) and (ii) missed visit (returning to care 14-56 days late for a 
scheduled visit). 
 
Results: A total of 358 women (median age, 28 years; median gestational age at initiation, 26 
weeks) initiated ART during pregnancy. By six months postpartum 24% of women (n=86) had 
missed at least one visit and 32% (n=115) were LTF. Overall, 49% of women had either missed 
a visit or were LTF by six months postpartum.  LTF was more than twice as frequent postpartum 
compared to in the antenatal period (6.2 vs 2.4 per 100 woman-months, respectively; p=0.0004). 
In a proportional hazards model, later gestational age at initiation (HR: 1.04; 95% CI: 1.00-1.07; 
p=0.030) and being newly diagnosed with HIV (HR: 1.57; 95% CI: 1.07-2.33; p=0.022) were 
significant predictors of LTF after adjusting for patient age, starting CD4 cell count and site of 
ART initiation. Site of ART initiation was not a significant predictor of LTF. 
 
Conclusions: These results demonstrate that missed visits and LTF occur frequently among 
HIV-infected women initiating ART during pregnancy, particularly post-delivery. Further 
research is required to understand reasons for non-adherence and LTF and the implications 
thereof in the context of pregnancy. Women newly diagnosed with HIV and those presenting at 
later gestational ages may be particularly vulnerable and there is an urgent need for interventions 





Mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) is the main 
contributor to new HIV infections in children globally. In 2012, 260 000 children were newly 
infected with HIV and 90% of these new infections occurred in Sub-Saharan Africa (SSA) [1].  
In South Africa in particular, 30% of all women presenting for antenatal care (ANC) are HIV-
infected [2]. Vertical transmission can take place in utero, intrapartum and postpartum through 
breastfeeding; and throughout, maternal viral load is a key determinant of MTCT risk. 
Antiretroviral therapy (ART) is known to be a highly effective method of achieving viral 
suppression and is highly efficacious in preventing MTCT, in addition to having well-known 
benefits for maternal health [3,4]. Use of ART by HIV-infected pregnant women is currently the 
standard of care worldwide and the latest South African national PMTCT guidelines recommend 
immediate ART initiation in all pregnant and breastfeeding women [5]. 
The success of ART for PMTCT hinges on eligible women starting treatment timeously during 
pregnancy and maintaining ongoing adherence to ART throughout pregnancy and breastfeeding. 
Uptake of ART during pregnancy has improved dramatically with the introduction of ART 
services integrated into ANC [6–9]. Integrated ART has also resulted in earlier ART initiation, 
increasing the time on treatment prior to delivery and further reducing the risk of MTCT [10–
14]. Poor ART adherence and loss to follow-up (LTF) undermine the potential benefits of 
maternal ART use during pregnancy and/or breastfeeding and confer increased risk of both 
MTCT as well as maternal morbidity and mortality [15].  
Several studies have suggested that levels of ART adherence may be lower, and/or LTF higher, 
in pregnant and postpartum women compared to non-pregnant adults initiating ART [16–19]. 
There is a particular concern regarding adherence and LTF in the postpartum period [7,20,21], 
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when women may encounter multiple barriers to remaining in care and adherent to treatment 
[21–24]. These concerns, coupled with new policies that call for expanded access to lifelong 
ART in HIV-infected pregnant women [15], mean that there is an urgent need for additional data 
on ART adherence and retention in care among women initiating ART during pregnancy.  
This study investigated retention in care, including LTF and missed ART dispensing visits, 
following ART initiation by pregnant women in Cape Town, South Africa. The first objective 
was to describe the occurrence of LTF and missed visits from ART services during pregnancy 
and up to six months postpartum. The second objective was to investigate socio-demographic, 
obstetric and clinical characteristics, as well as health services factors, in particular integrated 
and non-integrated ART initiation sites, as possible predictors of retention in ART services. 
 
2 Methods 
2.1 Study setting 
We conducted a retrospective cohort study at a large primary health care antenatal clinic in 
Gugulethu, Cape Town. Historically, all women found to be ART eligible during ANC were 
referred to a nearby general adult ART clinic for treatment initiation [10,14,25]. In January 2012, 
integrated nurse-initiated and managed ART (NIMART) services were introduced at the 
antenatal clinic. From this time onwards, all eligible women started ART in the ANC facility 
where they continued to receive their ART care along with ANC throughout the antenatal period. 
Following delivery, women were transferred to general adult ART services after the latter of 
either 20 weeks on treatment or when the infant HIV status had been determined at six weeks of 
age.  Clinical protocols did not differ between the general ART service and the ANC-based ART 
service but there were slight variations in pre-ART counselling procedures: Women who were 
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referred to the general ART service received two counselling sessions at weekly intervals prior to 
initiation, while women starting ART in the ANC clinic received one pre-ART counselling 
session 1-2 weeks before initiation, with additional counselling on the day of initiation. Pre-ART 
counselling was provided by the same team of counsellors working at both services. 
Throughout the study period, pregnant HIV-infected women who were eligible for ART were 
started on a combination of tenofovir with lamivudine and either nevirapine or efavirenz [26]. 
ART eligibility was based on CD4 cell count of ≤350 cells/µl or WHO stage III/IV disease 
throughout the review period. At both ART sites women received a 30 day supply of ART for 
the first four months on treatment and 30-60 day supply thereafter. Visits were scheduled every 
28 or 56 days depending on the quantity of ART dispensed. 
2.2 Data collection 
Data for this analysis come from a review of routine medical records for all women who initiated 
ART during pregnancy between January 2011 and September 2012. Demographic, obstetric and 
clinical characteristics, as well as the ART initiation site and details of visit attendance 
(including dates of clinic visits, scheduled visits and quantity of ART supplied at each visit) were 
abstracted from routine medical records at both ART facilities using standardized data 
abstraction tools (see Appendix A & B). Data were abstracted up to 12 months on ART and 
missing data were obtained from the National Health Laboratory Service (NHLS) database.  
2.3 Data analysis 
Data were entered into a Microsoft Access database and analysed using Stata 12.0 (Stata 
Corporation, College Station, USA). Descriptive statistics were used to summarise the baseline 
characteristics of the study population. Bivariate associations were calculated using chi-squared 
tests for categorical variables and the Wilcoxon rank-sum test for independent samples of 
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continuous variables. The primary exposure of interest was the site of ART initiation, analysed 
as a binary variable denoting general adult ART initiation or ART initiation integrated into ANC. 
The quantity of ART supplied at each visit was used to determine the next expected visit date 
and the number of days late were calculated as the difference between the expected ART visit 
and the date the visit was attended.  
We used time-to-event analysis to investigate LTF in the antenatal and postpartum periods. The 
primary outcome LTF was defined as having 56 days elapsed since the last scheduled visit with 
no evidence of attendance, treatment collection or transfer out (TFO) [10,27,28].1 For the 
purpose of this analysis, women transferred out during the analysis period were considered 
retained and were censored at the time of transfer out2. Secondary analyses focused on missed 
visits as a marker of non-adherence, defined as being more than 14 days late for a visit but 
returning to care within 56 days. Antenatal person-time was accrued from ART initiation to the 
first of: (i) Delivery; (ii) TFO or (iii) LTF. For women remaining in care postpartum, person-
time accrued from the date of delivery up to the first of: (i) The end of the study period; (ii) TFO 
or (iii) LTF. The date assigned to LTF was the date of the last expected visit. Kaplan Meier 
curves were generated to explore retention in the antenatal and postpartum periods and between 
the two ART initiation sites. Predictors of LTF overall, as well as restricted to the antenatal or 
postpartum periods, were examined using Cox proportional hazards models, with results reported 
as adjusted hazard ratios (aHR) with 95% confidence intervals (CI). Time-varying covariates 
were used to examine the impact of pregnancy status (antenatal versus postpartum) on retention. 
  
1 In a sub-analysis, LTF was defined as having 28 days elapsed since the last scheduled visit. These results are 
presented in the appendix however they did not differ substantively from those presented based on LTF as 56 days 
elapsed since the last scheduled visit. 
2 Descriptive characteristics stratified by outcomes retained, transferred out and LTF are presented in the appendix. 
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Ethical approval to abstract data and conduct this analysis was provided by the Human Research 
Ethics Committee of the University of Cape Town. As part of the routine services in this setting, 
all women screened for ART also complete an informed consent document allowing their 
anonymous health care information to be used in research. 
 
3 Results 
A total of 358 women initiated ART in pregnancy during the study period and were included in 
the analysis. The median age and gestational age at ART initiation were 28 years (IQR 26-33) 
and 26 weeks (IQR 21-31), respectively (Table C-1). Most women had at least secondary level 
education and only 28% of women were employed. Overall, 207 women (58%) were newly 
diagnosed as HIV-infected in the current pregnancy. Among the 315 women (88%) for whom 
relationship status was available, 77% reported being in a relationship and the majority of 
women had disclosed their HIV status to at least one person at the time of ART initiation. The 
median CD4 cell count at the time of screening for ART eligibility was 233 cells/µl (IQR 157-
287) and 88% of women were classified as WHO clinical stage I or II at the time of ART 
initiation. Among women for whom parity was available (94%), 19% were primigravid and the 
median parity was 1 (IQR 1-2). History of antiretroviral (ARV) use was available for 350 women 
(98%) of whom 45% were ARV naïve, 5% had defaulted ART previously and 50% had previous 
exposure to ARV prophylaxis for PMTCT only. 
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Table C-1: Demographic, obstetric and clinical characteristics of 358 participants stratified by 
site of ART initiation 
  General adult ART 
initiation site 
n (%) or median (IQR) 
ANC ART initiation 
site 
n (%) or median (IQR) 
p-value* Total 
 
n (%) or median (IQR) 
Number of women 142  (40) 216 (60) - 358  
Total woman months of observation 1077 (44)  1369 (56) - 2446   
Demographics        
Age (years)  28 (25-33) 28 (26-33) 0.829 28 (26-33) 
Level of education              
Primary 13 (9) 10 (5) 0.100 23 (6) 
Secondary/Tertiary 128 (90) 199 (92)   327 (91) 
Missing 1 (1) 7 (3)   8 (2) 
Employment status     0.838    
Employed 42 (30) 59 (27)   101 (28) 
Missing 2 (1) 26 (12)   28 (8) 
Relationship status3     0.014    
In a relationship 115 (81) 160 (74)   275 (77) 
Missing 2 (1) 41 (19)   43 (12) 
HIV history        
Time of HIV diagnosis         
Diagnosed in current pregnancy 75 (53) 132 (61) 0.068 207 (58) 
Missing 0 (0) 5 (2)   5 (1) 
Disclosure status         
Disclosed 129 (91) 174 (81) 0.021 303 (85) 
missing 1 (1) 6 (3)   7 (2) 
Previous ARV use         
No exposure 44 (31) 114 (53) <0.001 158 (44) 
Previous ART 9 (6) 10 (5)   19 (5) 
PMTCT only 88 (62) 87 (40)   175 (49) 
missing 1 (1) 5 (2)   6 (2) 
WHO stage at screening         
I/II 120 (85) 194 (90) 0.135 314 (88) 
III/IV 22 (15) 22 (10)   44 (12) 
CD4 cell count at screening 233 (157-285) 230.
5 
(157-291) 0.944 233 (157-287) 
Obstetric characteristics        
Parity  1 (1-2)  1 (1-2) 0.195 1 (1-2)  
Primigravid  28 (20) 40 (19)   68 (19) 
Missing 19 (13) 2 (1)   21 (6) 
Gestational age at initiation 28 (23-32) 25 (20-30) 0.006 26 (21-31) 
ARV, antiretroviral; ART, antiretroviral therapy; WHO, World Health Organization 
*Bivariate comparisons using chi-squared and Wilcoxon rank sum tests. Missing data excluded. 
 
  
3 Relationship status has only been included in descriptive tables. It has been omitted from models due to 
inconsistencies and missing values in the data. 
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In total, 142 women started ART in a general adult ART service while 216 women started ART 
within the ANC clinic. There was no significant difference in age, parity, education or 
employment status in the two groups. Compared to pregnant women who started ART in a 
general ART clinic, women who started ART in the ANC clinic were more likely to be ARV 
naïve (p<0.001). Among women starting ART in the ANC clinic, 61% had been newly 
diagnosed with HIV in the current pregnancy compared to 53% of women referred out to start 
ART (p=0.068). Women starting ART in the ANC clinic also tended to have a lower WHO 
clinical stage at ART initiation (p=0.036), although there was no significant difference in 
screening CD4 cell count between the two groups. Disclosure was common in both groups, 
however the proportion of women who had disclosed was significantly higher among women 
initiating in a general adult ART clinic compared to women starting within ANC (p=0.021).  
Descriptive characteristics of all women stratified by their final retention status in the primary 
analysis are displayed in Table C-2. Of 358 women included in the analysis, 115 women (32%) 
were LTF while 243 (68%) were either still in care at the ART initiation site or had been 
transferred out (TFO) before six months postpartum. Demographic characteristics were similar 
between women retained and those LTF. Among the women retained in care, 54% had been 
newly diagnosed with HIV, compared to 65% new diagnoses among women LTF (p=0.060). 
Median gestational age at ART initiation was lower among women who were retained (25 weeks 
IQR: 20-30), compared to those LTF (28 weeks IQR: 21-32). 
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Table C-2: Demographic, obstetric and clinical characteristics of 358 participants stratified by 
final retention status 
  Lost to follow up 
n (%) or median (IQR) 
Retained 
n (%) or median (IQR) 
p-value* 
Number of women 115  (32) 243  (68) - 
Total woman months of observation 508  (21) 1938  (79) - 
Integrated ANC/ART initiation site 66 (57) 150 (62) 0.433 
Demographics      
Age 28 (24-33) 28 (26-33) 0.576 
Level of education          
Primary 6 (5) 17 (7) 0.568 
Secondary/Tertiary 104 (91) 223 (92)   
missing 5 (4) 3 (1)   
Employment status      
Employed 38 (33) 63 (26) 0.155 
missing 9 (8) 19 (8)   
Relationship status      
In a relationship 85 (74) 190 (78) 0.277 
missing 21 (18) 22 (9)   
HIV history      
Time of HIV diagnosis      
Diagnosed in current pregnancy 75 (65) 132 (54) 0.060 
missing 1 (1) 4 (2)   
Disclosure status      
Disclosed 99 (86) 204 (84) 0.629 
missing 2 (2) 5 (2)   
Previous ARV use      
No exposure 51 (44) 107 (44) 0.640 
Previous ART 8 (7) 11 (5)   
PMTCT only 55 (48) 120 (49)   
missing 1 (1) 5 (2)   
WHO stage at screening      
I/II 100 (87) 214 (88) 0.765 
III/IV 15 (13) 29 (12)   
CD4 cell count at screening 248 (151-290) 228 (159-285) 0.568 
Obstetric characteristics      
Parity  1 (1-2)  1 (1-2) 0.719 
Primigravid  24 (21) 44 (18)   
Missing 9 (8) 12 (5)   
Gestational age at initiation 28 (21-32) 25 (20-30) 0.027 
ARV, antiretroviral; ART, antiretroviral therapy; WHO, World Health Organization 
*Bivariate comparisons using chi-squared and Wilcoxon rank sum tests. Missing data excluded. 
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Outcomes by ART initiation site are displayed in Table C-3. In the primary analysis, 32% of 
women were LTF (having 56 days elapsed from the last scheduled visit and no evidence of 
attendance) and 24% of women experienced a missed visit (returning to care 14-56 days after the 
scheduled visit date).  Overall, 49% of women were either LTF or had at least one missed visit 
before six months postpartum. Rates of LTF were lower in the antenatal period (2.41 per 100 
woman months) compared to postpartum (6.17 per 100 woman months). The difference between 
postpartum and antenatal rates of LTF was higher among women who started ART in the ANC 
clinic (Rate ratio 4.09) compared to those starting at a general adult service (Rate ratio 1.42).  
Table C-3: Outcomes stratified by site of ART initiation 
  General adult ART 
initiation site 
n (%) or rate (95% CI) 
ANC ART initiation 
site 
n (%) or rate (95% CI) 
Total 
 
n (%) or rate (95% CI) 
Overall analysis period (ART initiation to six month postpartum) 
Number of women 142 (40) 216 (60) 358   
Total woman months of observation 1077 (44)  1369 (56) 2446   
Retained (including TFO)  93 (65) 150 (69) 243 (68) 
Lost to follow-up 49 (35) 66 (31) 115 (32) 
Rate of LTF per 100 woman months 4.55  (3.44-6.02) 4.82 (3.79-6.14) 4.70 (3.92-5.64) 
One or more missed visit  50 (35) 36 (17) 86 (24) 
Antenatal period (ART initiation to delivery)         
Number of women 142  216  358   
Total woman months of observation 340  616  956   
Retained (including TFO) 130 (92) 205 (95) 335 (94) 
Lost to follow-up 12 (8) 11 (5) 23 (6) 
Rate of LTF per 100 woman months 3.53 (2.00-6.22) 1.79 (0.99-3.23) 2.41 (1.60-3.62) 
One or more missed visit  7 (5) 11 (5) 18 (5) 
Postpartum period (delivery to six months postpartum) 
Number of women 127  205  332   
Total woman months of observation 737  753  1490   
Retained (including TFO) 90 (71) 150 (73) 240 (72) 
Lost to follow-up 37 (29) 55 (27) 92 (28) 
Rate of LTF per 100 woman months 5.02 (3.64-6.93) 7.30 (5.61-9.51) 6.17 (5.03-7.57) 
One or more missed visit  43 (34) 27 (13) 70 (21) 
ART, antiretroviral therapy; TFO, transfer out; LTF, loss to follow-up 
 
Retention in care by site of treatment initiation is presented in Kaplan Meier curves for the 
overall, antenatal and postpartum periods (Figure C-1). Among women LTF after delivery, the 
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median time to loss was 57 days postpartum (IQR 9-97). Rates of LTF appeared similar in 
women who started ART in the general ART clinic compared to those initiated in the ANC 
overall (Figure C-1a) and postpartum (Figure C-1c). During the antenatal period, LTF appeared 
higher among those who started ART in a general ART clinic, though this difference was not 
statistically significant (p=0.054; Figure C-1b). Retention in care in the antenatal and postpartum 
periods is shown by model of ART initiation in Figure C-2, where the bold lines represent 
initiation at the general ART initiation site and the thin lines represent integrated ART initiation 
at the antenatal clinic. Overall, the cumulative probability of LTF was higher in the postpartum 
period regardless of the model of ART initiation (p=0.0004). 
 
Figure C-1: Kaplan Meier curves of the probability of retention in care for a) ART initiation to 
six months postpartum, b) ART initiation to delivery and c) delivery to six months postpartum. 




Figure C-2: Kaplan Meier curve of retention during the antenatal and postpartum periods by 
ART initiation site 
 
In proportional hazard models (Table C-4) the site of ART initiation was not a significant 
predictor of LTF overall, antenatally or in the postpartum period. Only gestational age at ART 
initiation and time of HIV diagnosis were identified as significant predictors of LTF overall and 
after delivery. Overall, after adjusting for age, time of HIV diagnosis, CD4 cell count at 
screening, site of initiation and being in the postpartum period, a one week increase in 
gestational age at ART initiation was associated with a 4% increased hazard of being LTF by six 
months postpartum (aHR: 1.04 CI: 1.00-1.07). Women newly diagnosed with HIV in the current 
pregnancy had a 57% increased hazard of LTF overall compared to women with known HIV 
infection (aHR: 1.57 CI: 1.07-2.33). There was an almost four fold increase in the hazard of 
being LTF postpartum compared to that found in the antenatal period (aHR: 3.93 CI: 1.25-
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Table C-4: Proportional hazard models predicting LTF according to participant demographic, 
obstetric and clinical characteristics in (a) the overall analysis period, and restricted to (b) the 
antenatal period and (c) the postpartum period  
  A) Crude associations B) Adjusted associations4 
  HR (95% CI) p-value aHR (95% CI) p-value 
a) Overall analysis period (ART initiation to six month postpartum) 
Age 0.99 (0.95-1.02) 0.517 0.99 (0.95-1.03) 0.554 
Employed 0.80 (0.54-1.19) 0.263     
Diagnosed in current pregnancy 1.56 (1.06-2.30) 0.024 1.57 (1.07-2.33) 0.022 
Have not disclosed 0.96 (0.55-1.68) 0.879     
ARV history                          
No exposure 1 (ref)       
Previous ART 1.11 (0.53-2.35) 0.778     
PMTCT only 1.02 (0.70-1.50) 0.912     
WHO clinical stage III/IV 0.97 (0.74-1.27) 0.802     
Screening CD4 1.00 (0.999-1.003) 0.570 1.00 (0.999-1.003) 0.453 
Parity 0.98 (0.79-1.20) 0.824    
Gestational age 1.05 (1.02-1.08) 0.001 1.04 (1.00-1.07) 0.030 
Integrated ART 1.03 (0.70-1.49) 0.897 1.14 (0.77-1.69) 0.506 
Postnatal                             2.75 (1.56-4.88) 0.001 3.93 (1.25-12.31) 0.019 
b) Antenatal (ART initiation to delivery) 
Age 0.99 (0.91-1.08) 0.866 0.99 (0.91-1.08) 0.860 
Employed 2.24 (0.65-7.63) 0.199     
Diagnosed in current pregnancy 1.25 (0.52-2.98) 0.613 1.28 (0.53-3.09) 0.576 
Have not disclosed 0.58 (0.14-2.48) 0.462     
WHO clinical stage III/IV 0.59 (0.22-1.62) 0.307     
Screening CD4 1.00 (0.99-1.00) 0.449 1.00 (0.99-1.00) 0.514 
Parity 1.04 (0.66-1.64) 0.863     
Gestational age 1.06 (0.98-1.16) 0.145 1.06 (0.97-1.15) 0.193 
Integrated ART 0.45 (0.19-1.04) 0.062 0.48 (0.21-1.13) 0.093 
c) Postpartum (delivery to six months postpartum)  
Age 0.98 (0.94-1.02) 0.391 0.99 (095-1.03) 0.472 
Employed 0.68 (0.44-1.04) 0.077     
Diagnosed in current pregnancy 1.58 (1.03-2.44) 0.038 1.59 (1.03-2.46) 0.038 
Have not disclosed 1.08 (0.59-1.99) 0.796     
ARV history                          
No exposure 1 (ref)       
Previous ART 1.25 (0.59-2.67) 0.562     
PMTCT only 0.92 (0.60-1.41) 0.691     
WHO clinical stage III/IV 1.04 (0.78-1.38) 0.788     
Screening CD4 1.00 (0.999-1.004) 0.291 1.00 (0.999-1.004) 0.236 
Parity 0.95 (0.74-1.20) 0.651     
Gestational age 1.04 (1.01-1.08) 0.012 1.05 (1.01-1.08) 0.008 
Integrated ART 1.24 (0.81-1.89) 0.318 1.31 (0.85-2.02) 0.224 
ART, antiretroviral therapy; ARV, antiretroviral; prevention of mother-to-child transmission, PMTCT; WHO, World Health 
Organization 
4 Multivariate models were adjusted for age, ART initiation site, gestational age at ART initiation, screening CD4 cell count and 
time of HIV diagnosis. Pregnancy status (antenatal/postnatal) was included as a time varying covariate in the overall multivariate 
analysis. ARV history was excluded from the antenatal model as there were insufficient observations in each category. 
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4 Discussion 
This analysis suggests that by six months postpartum, almost half of women had either missed at 
least one scheduled visit or were LTF after initiating ART during pregnancy and that LTF was 
substantially more common postpartum compared to before delivery. In the context of pregnancy 
and PMTCT, these gaps in care have serious implications for the risk of vertical transmission as 
well as maternal health.  
While outcome definitions vary between studies, these findings are broadly consistent with the 
results of previous studies indicating high levels of non-retention and/or non-adherence, 
particularly postpartum [21,27]. Two significant predictors emerged for risk of LTF in this 
analysis. Firstly, women newly diagnosed with HIV in pregnancy were more likely to be LTF 
than women who had previously been diagnosed with HIV. This echoes previous research 
suggesting substantial challenges related to coping with an HIV diagnosis in pregnancy 
[23,28,29]. In turn, this points to the need for interventions that support women newly diagnosed 
with HIV during pregnancy. Secondly, later gestational age at initiation was found to be a 
predictor of LTF through six months postpartum. While the mechanisms underlying this require 
further investigation, it is possible that late gestation at ART initiation reflects suboptimal health-
seeking behavior more generally [30,31]. This would suggest that women who seek ANC and/or 
initiate ART late in pregnancy are a high-risk population that requires special attention 
throughout the postpartum period of breastfeeding. 
Women receiving care in the integrated service started ART earlier in gestation.  Earlier 
gestational age at initiation was found to be a predictor of retention in this analysis, however 
levels of LTF were similar among women in both ART initiation groups overall. In the antenatal 
period the rate of LTF was lower among women who received integrated ART compared to 
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women who were referred out for ART (1.82 and 3.59 women LTF per 100 women months 
respectively, p=0.054). This may be explained by a lower burden of health care visits as well as 
improved relationships with health care providers in an integrated ART/ANC service [32,33]. 
Further research is required to fully explore the impact of timing of ART initiation and integrated 
service delivery on retention in care both during pregnancy and after delivery. 
Linking women to ART care from ANC services is known to be a challenge. Although women in 
this analysis were considered to be retained in care at the time of TFO, it is important to note that 
women transferred in the early postpartum period may be particularly vulnerable to LTF. 
Studies, including the presented analysis, have found that women are at a higher risk of LTF 
and/or non-adherence post-delivery compared to during pregnancy [21,27]. This, coupled with 
the known challenges of linking women to general adult ART care, may be cause for concern 
[22,34]. Research on postpartum linkage to general ART services is necessary in the context of 
integrated antenatal ART.  
Several important limitations should be considered with the presented findings. The sample size 
may limit the power of the analysis to detect small associations involving measured covariates. 
All data were collected from review of routine medical records and not all covariates were 
routinely measured and recorded in this setting. Related to this, recording of reasons for late or 
missed visits is not routine and it was not possible to explore reasons for late visit attendance. 
The retrospective design of this study made it possible to include two sequential cohorts of 
women initiating ART, first at general adult ART services and then in an integrated antenatal 
ART service. However, without randomization or simultaneous enrolment at the two ART sites, 
changes in care provision over time could not be controlled for in this analysis. 
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This analysis is limited to a cohort of women known to have initiated ART during pregnancy; a 
select group who successfully linked from ANC to ART services. LTF prior to ART initiation in 
pregnancy is known to be high [8,35] and our estimates of LTF and missed visits are likely to be 
an underestimation as a result of this selection bias. The rate of LTF in this analysis may be an 
overestimate if women who were considered LTF have returned to care after the end of the study 
period or moved to other facilities without formal transfer. Recent studies have suggested that 
not all patients considered LTF are truly no longer in care [24,36].  Kranzer et al. found that 
approximately one third of patients thought to be LTF returned to care in a general adult ART 
programme in South Africa [36]. In addition, this analysis focused on missed visits and LTF but 
there are other important PMTCT outcomes, in particular infant HIV-infection, which we have 
not examined.  
Despite the limitations of routinely collected medical records, this study took place in a large, 
representative primary health care facility where visit attendance and pharmacy records were 
well completed. In turn, these data represent a ‘real-world’ estimate of the timing of 
disengagement from primary care services in this setting, however further research into the 
frequency, predictors and prevention of LTF from ART care during pregnancy and postpartum 
are clearly required.  
In conclusion, these results demonstrate that missed visits and LTF occur frequently among HIV-
infected women who have initiated ART during pregnancy, particularly in the post-partum 
period. With the promotion of breastfeeding and a shift to lifelong ART for all pregnant HIV-
infected women in SSA, these data highlight the importance of promoting postpartum adherence 
for PMTCT as well as for ongoing maternal health. While additional research is required, women 
newly diagnosed with HIV and those presenting for ANC or ART at later gestational ages may 
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be particularly vulnerable and there is an urgent need for interventions to promote adherence and 
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Appendix A: Data abstraction forms 




Year (by CD4 count on referra l) 
HCTC Folder number 
Provincial Folder number 
Da B 
Level of education (1) Primary, (2) Secondary, (3) Tertiary 
Hx of ARV (1) NaN e, (2) Non-naiVe, (3) PMTCT 
Employment (1) Employed , (2) Unemployed 
Disclosure status (1) Yes, (2) No 
(1) Partner, (2) Other fa mily member, (3) Employer (4) 
Disclosure to whom Community, (5) Other household member, (6 ) Friend, (7 ) Other 
Relationship status (1) Single (2) Married (3) Separated (4) W idowed 
Partner tested (1) Yes, (2) No 
Partner status (1) Positive , (2) Negative 
Partner on ARVs (1) Yes, (2) No 
WHO staQe (1) I, (2) II, (3) III , (4) IV 
Gestational age 
Date of 1st HIV diagnosis? 
Newly diaQnosed with H IV? 
Date of 1st CD4 (bookinQ ) 
CD4 count (1st) 
Date of 2nd CD4 (-4-2) 
CD4 count (2nd) 
Vira l load (if available ) 
Date of referral letter from MOU/other 
Date of ARV screeninQ (-4-2) 
Date of HAART initiation 
(1) Yes 
Not screened until postpartum? 
Did not initiate treatment until (l ) Yes 
postpartum? 




Referred from site other than Gugs (1) Yes, (2) No 
MOU? 
If so, referra l Source 
Notes 
Form 2 – page 1: ART visits and delivery outcomes 
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Site Name: 
Maternal ART retent ion 
Data Abstraction Fo rm V1.4 
Data collected by: 
Linkage phase: routine f EL f NIMART Date of data collection: __ '-_ ---1 ____ 
• • " " " , , , , 
1. Folder # 2 . DOB: 
__ '-_ ---1 ____ 
• • " " " , , , , 
3. ART care site at HC=1 4 . Gestational age at 
initiation? initiation(week 0) 
Gugulethu MOU = 2 
Pregnancy details 
Live Birth = 1 
5. Gravidity & Parity 
G -
6. Pregnancy outcome Still Birth = 2 
P -
NR= 5 
Gugulethu MOU = 1 
__ '-_ ---1 ____ MMH = 2 
•• " " " , , , , 7. Date of delivery 8. Delivery Site GSH = 3 
NR = 5 
Other = 4. spedfy: 
NR= 5 
Retention status 
Documented death = 1 
Transferred out = 2 
9. Date of last __ '-_ ---1 ____ 
10. Status at last contact Stopped treatment = 3 
contact •• " " " , , , , 
Unknown = 4 
Retained = 5 
Still pregnant = 1 12. If transferred: 
11. Pregnancy status 
Delivered = 2 
Date of transfer out __ '-_ ---1 ____ 
at last contact of MOU • • " " " , , , , 
Unable to determine = 5 (DD/MMlYY) 
13. Referred to: Clinic name: 
14 . Other comments: 
Infant PCR 
Nonreactive = 0 
15. lnfantSweek PCR Reactive = 1 1S. PCR date __ '-_ ---1 ____ 
• • " " " , , , , NR = 5 
 Form 2- page 2: ART visits and delivery outcomes
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Folder If : _____________ _ 
Date 01 da t a abstract io n: __ 1 __ -1 ___ _ Perso n abst ract ing data : ________ _ 
Instru ct ions: List all ART visits from ART screening and the result of any routine bloods. Note if tile pattidpant is a known defaulter, was 
transferred out at that visit or any other points of interest (maternal death loss of pregnancy) 
L '" L. Date vi.it ,. w, o •• "" ,. Viral •• ART .upply , . Known •• Com ment : VISITS IOO/ MM/ YV I Stage load di.pen",d defaulter Not .. any re a. o n. given for 
le8 1/ 12) mi .... d vi. it. 
·4·2 
Appendix B: Ethics approval forms 
UCT HREC 359/2002 
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FACUL TV OF HEALTH SCIENCES 
Hum,n Res.,<d\ EtINa Comtn;tt .... 
Annual Progress Report 
REC REF Number 35912002 
Title Data collection at the Hannan Crusaid ART treatment Centre in 
Gugu lethu and at the Maslphumetele ART roU-out siles 
Principal Catherine Orrell Robin Wood 
list of documentation 
• Updated FHS016 form - January 2013 
• Cover letter listing current collaborators - January 2013 . 
H""~~ RE5CA::O< 
r r 
1 1 JAN 2013 
HE'"- H C ( 
1 
UMVER ,lTV . . ; CA 'TC\I~J - ---
W o"',. us. o",y~ 
"" ~ " U N,n 
, ". m re,,,. I U ID I 
,~""" 
/ Datu 71 (, h, ) ~or"'HREC -
25 FellNory 2009 FHSOl8 
UCT HREC 391/2010 
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UNIVUSIJY OF CAPE TO N HUMAN RESEARCH 
" ... ,' .... , .. .......... ,', ..... , .. », ETHICS CO~I'lmEE FAC LTV OF HEALTH SCIENCE s -
HUlT\il ro Re5e8rth EtIIla COmmltt 
FHS016: "nnuol UJl~'e~W~eport Renewal 
~, - r_,_ .. -
HREC office UI. only tFWAOOO0163,Z; IRIlQO:g(l't3@r CAPE TOWN 
This leN" as notification of annual approval, Including any documentation described below. 
. '" A"""",ed Annual progress report Approved unllVnelCt renewal date 
o Not approved See attached ct>mments 
SlQnalureChalrperson of the HREC ! ././~/ 
Principal Investigator to complete the following : 
1 Protocol information 
Date form submitted 1;1/" L 
! Date Signed 
lo.1l~IOCl3 
I~tqt'z-
HREC REF Number 3~ 1 ']11101 I Current Ethics Approval was granted until I 74/f/ l / 
Protocol tille cJrj.,~1 ,.j"y fv (l1Yl7C-"'-"';;; J' w-Jt, 
IJ,C. 
- -
Protocol :'lumber (If 
applicable) 
Pnl'lClp3llnve&tJgator 4-/ IM- ~ l Mii?f2. ~PH. </ F ""-
Department / Office '>9\-1 <! l'-"" 1 ~".,.".., 4-h h) ~ • ~~ Internal Mall Address 
1 1 Does !hIs protocot receive US Federal funding? o Ves I~ 
1 2 Has sponsorship of thl' stud~ changed? If yes, please attach a revised o Ves ~ 
summary of the budget. 
2. list of documentation 
~ 
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Appendix C: Sub-analysis 
1. Comparison of  women lost to follow-up, transferred out and retained at ART initiation 
site 
Table D-1: Demographic, obstetric and clinical characteristics of 358 participants stratified by 
final retention status 
  Lost to follow up 
n (%) or median (IQR) 
Retained at ART site 
n (%) or median (IQR) 
Transferred out 
n (%) or median (IQR) 
p-value* 
Number of women 115  (32) 97  (27) 146 (41) - 
Total woman months of observation 508  (21) 995  (41) 943 (39)  - 
Integrated ANC/ART initiation site 66 (57) 17 (18) 133 (91) <0.0001 
Demographics        
Age 28 (24-33) 29 (26-33) 28 (26-32) 0.595 
Level of education            
Primary 6 (5) 9 (9) 8 (6) 0.449 
Secondary/Tertiary 104 (91) 88 (91) 135 (92)  
missing 5 (4) 0 (0) 3 (2)  
Employment status        
Employed 38 (33) 29 (30) 34 (23) 0.291 
missing 9 (8) 2 (2) 17 (12)   
Relationship status        
In a relationship 85 (74) 78 (80) 112 (77) 0.180 
missing 21 (18) 2 (2) 20 (14)   
HIV history        
Time of HIV diagnosis        
Diagnosed in current pregnancy 75 (65) 43 (44) 89 (61) 0.003 
missing 1 (1) 0 (0) 4 (3)   
Disclosure status        
Disclosed 99 (86) 89 (92) 115 (79) 0.013 
missing 2 (2) 2 (2) 3 (2)   
Previous ARV use        
No exposure 51 (44) 36 (37) 71 (49) 0.244 
Previous ART 8 (7) 7 (7) 4 (3)   
PMTCT only 55 (48) 52 (54) 68 (47)   
missing 1 (1) 2 (2) 3 (2)   
WHO stage at screening        
I/II 100 (87) 77 (79) 137 (94) 0.003 
III/IV 15 (13) 20 (21) 9 (6)   
CD4 cell count at screening 248 (151-290) 215 (147-276) 232 (173-285) 0.636 
Obstetric characteristics        
Parity  1 (1-2)  1 (1-2) 1 (1-2) 0.715 
Primigravid  24 (21) 18 (19) 26 (18)   
Missing 9 (8) 9 (90 3 (2)   
Gestational age at initiation 28 (21-32) 27 (22-32) 24 (20-29) 0.003 
ARV, antiretroviral; ART, antiretroviral therapy; WHO, World Health Organization 
*Bivariate associations were calculated using chi-squared tests for categorical variables and the Kruskal Wallis test 
for multiple independent samples of continuous variables. 
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The table presented here displays descriptive characteristics of all 358 women included in the 
analysis, stratified by outcome where being transferred out was treated as an independent 
outcome category (Table D-1). Overall, 41% of women were transferred out, 27% retained at the 
ART initiation site and 32% were LTF by six months postpartum. The overwhelming majority 
(91%) of women transferred out before six months postpartum started ART in the integrated 
service. This table corresponds to Table C-2 in the results section of the manuscript (Part C, page 




2. Results with an alternative definition of loss to follow-up 
In this sub-analysis, loss to follow-up (LTF) was defined as having more than 28 days elapse 
after missing a scheduled ART visit. Table D-2 below corresponds to Table C-3 in the results 
section of the manuscript (Part C, page 67), where LTF is defined as being more than 56 days 
late for a scheduled ART visit. The results of both analyses were similar. As expected, estimates 
of LTF were higher using the earlier 28 day definition and LTF occurred more frequently in the 
postpartum period compared to the antenatal period. Overall in this analysis, 43% of women 
were LTF by six months postpartum. 
Table D-2: Outcomes stratified by site of ART initiation 
 
  
 General adult ART 
initiation site 
n (%) or rate (95% CI) 
ANC ART initiation 
site 
n (%) or rate (95% CI) 
Total 
 
n (%) or rate (95% CI) 
Overall analysis period (ART initiation to six month postpartum) 
Number of women 142 (40) 216 (60) 358   
Total woman months of observation 913 (42)  1285 (58) 2199   
Retained (including TFO) 71 (50) 132 (61) 203 (57) 
Lost to follow-up 71 (50) 84 (39) 155 (43) 
Rate of LTF per 100 woman months 7.77 (6.16-9.81) 6.53 (5.28-8.09) 7.05 (6.02-8.25) 
Antenatal period (ART initiation to delivery)         
Number of women 142  216  358   
Total woman months of observation 331 (36) 599 (64) 930   
Retained (including TFO)  123 (87) 196 (91) 319 (89) 
Lost to follow-up  19 (13) 20 (9) 39 (11) 
Rate of LTF per 100 woman months 5.75 (3.67-9.01) 3.34 (2.15-5.17) 4.19 (3.06-5.74) 
Postpartum period (delivery to six months postpartum) 
Number of women 120  196  316   
Total woman months of observation 583 (46) 686 (54) 1269   
 Retained (including TFO) 68 (57) 132 (67) 200 (63) 
Lost to follow-up 52 (43) 64 (33) 116 (37) 
Rate of LTF per 100 woman months 8.92 (6.80-11.71) 9.33 (7.30-11.92) 9.14 (7.62-10.97) 
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Kaplan Meier curves displayed in Figure D-1 show that retention was consistently better among 
women who started ART integrated into ANC compared to women referred out for ART, 
however this difference was only statistically significant in the antenatal period (Figure D-1a; 
p=0.042). Figure D-2 shows that the probability of LTF was highest among postpartum women 
initiating ART in the general ART service and lowest among women in the integrated ART 
group in the antenatal period. Using this definition of LTF, 50% of women were LTF by three 
months postpartum in the referred out group. These figures correspond to Figure C-1 and Figure 
C-2 in the manuscript, section C of this document. 
 
Figure D-1: Kaplan Meier curves of the probability of retention in care  for a) ART initiation to six 






Figure D-2: Kaplan Meier curve of retention during the antenatal and postpartum periods by 
ART initiation site 
 
Proportional hazards models for the overall time from ART initiation to six months postpartum, 
the antenatal and the postpartum periods are presented in Table D-3. In the overall model and a 
model restricted to the postpartum period, being newly diagnosed with HIV and having a 
previous history of ART use were identified as predictors of LTF after adjusting for age, 
gestational age, screening CD4 cell count and site of ART initiation. Integrated ART initiation 
was protective against LTF in the univariate model but was no longer significant after adjusting 
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Table D-3: Proportional hazard models predicting LTF according to participant demographic, 
obstetric and clinical characteristics in (a) the overall analysis period, and restricted to (b) the 
antenatal period and (c) the postpartum period 
  A) Crude associations B) Adjusted associations5 
  HR (95% CI) p-value aHR (95% CI) p-value 
a) Overall analysis period (ART initiation to six month postpartum) 
Age 0.98 (0.95-1.01) 0.250 0.99 (0.96-1.02) 0.406 
Employed 0.80 (0.57-1.13) 0.204     
Diagnosed in current pregnancy 1.29 (0.93-1.79) 0.127 1.50 (1.06-2.13) 0.023 
Have not disclosed 1.14 (0.72-1.80) 0.590     
ARV history                          
No exposure 1 (ref)   1 (ref)   
Previous ART 2.13 (1.19-3.81) 0.010 2.40 (1.28-4.48) 0.006  
PMTCT only 1.26 (0.90-1.76) 0.176 1.20 (0.85-1.70) 0.305  
WHO clinical stage III/IV 0.97 (0.76-1.22) 0.771     
Screening CD4 1.00 (0.999-1.002) 0.667 1.00 (0.999-1.002) 0.445 
Parity 0.92 (0.76-1.10) 0.343    
Gestational age 1.04 (1.02-1.07) 0.001 1.01 (0.98-1.04) 0.474 
Integrated ART 0.82 (0.59-1.13) 0.221 0.94 (0.67-1.32) 0.706 
Postnatal                             3.06 (1.93-4.86) <0.001 5.85 (2.23-15.31) <0.001 
b) Antenatal (ART initiation to delivery) 
Age 0.97 (0.91-1.04) 0.349 0.97 (0.90-1.04) 0.379 
Employed 1.37 (0.62-3.00) 0.438     
Diagnosed in current pregnancy 1.12 (0.58-2.15) 0.731 1.28 (0.65-2.50) 0.476 
Have not disclosed 1.11 (0.46-2.65) 0.819     
ARV history                          
No exposure 1 (ref)   1 (ref)   
Previous ART 2.46 (0.82-7.42) 0.110 2.06 (0.64-6.60) 0.223  
PMTCT only 1.39 (0.70-2.74) 0.343 1.32 (0.65-2.67) 0.447  
WHO clinical stage III/IV 0.78 (0.43-1.41) 0.414     
Screening CD4 1.00 (0.995-1.002) 0.477 1.00 (0.995-1.002) 0.564 
Parity 0.92 (0.64-1.33) 0.649     
Gestational age 1.00 (0.94-1.07) 0.938 0.99 (0.93-1.06) 0.775 
Integrated ART 0.53 (0.28-0.99) 0.048 0.56 (0.29-1.09) 0.086 
c) Postpartum (delivery to six months postpartum)  
Age 0.98 (0.94-1.02) 0.257 0.99 (095-1.02) 0.406 
Employed 0.71 (0.48-1.04) 0.082     
Diagnosed in current pregnancy 1.32 (0.91-1.94) 0.142 1.56 (1.03-2.36) 0.036 
Have not disclosed 1.15 (0.67-1.98) 0.623     
ARV history                          
No exposure 1 (ref)   1 (ref)   
Previous ART 2.08 (1.05-4.12) 0.036 2.55 (1.20-5.42) 0.015 
PMTCT only 1.24 (0.84-1.83) 0.276 1.19 (0.80-1.79) 0.392 
WHO clinical stage III/IV 1.03 (0.79-1.33) 0.834     
Screening CD4 1.00 (0.999-1.003) 0.361 1.00 (0.999-1.004) 0.175 
Parity 0.88 (0.71-1.09) 0.255     
Gestational age 1.05 (1.01-1.08) 0.003 1.05 (1.01-1.08) 0.004 
Integrated ART 0.90 (0.62-1.30) 0.570 1.03 (0.70-1.51) 0.893 
5 Multivariate models were adjusted for age, ART initiation site, gestational age at ART initiation, screening CD4 
cell count, time of HIV diagnosis and history of ARV use. Pregnancy status (antenatal/postnatal) was included as a 
time varying covariate in the overall multivariate analysis. 
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the ProteomeExchange through the PRIDE website, and protein interaction data can be deposited through members 




Protein structures can be submitted with one of the members of theWorldwide Protein Data Bank. Nucleic acid 
structures can be deposited with the Nucleic Acid Database at Rutgers. Crystal structures of organic compounds can 
be deposited with the Cambridge Crystallographic Data Centre.  
 
Chemical structures and assays 
Structures of chemical substances can be deposited with PubChem Substance. Bioactivity screens of chemical 
substances can be deposited with PubChem BioAssay. 
 
Functional genomics data (such as microarray or CHIP-Seq data)  
Please refer to standards proposed by the Functional Genomics Data Society and deposit your microarray data in 
MIAME-compliant format in one of the public repositories, for example, ArrayExpress or Gene Expression 
Omnibus (GEO). Deposition of high-throughput functional genomics sequencing data (such as RNA-Seq or ChIP-Seq 
data) with ArrayExpress or GEO in compliance with MINSEQE is also needed. 
 
Computational modelling 
Please prepare models of biochemical reaction networks using the Systems Biology Markup Language and submit 
your model to theBioModels database, as well as providing it as an additional file with your submission. 
 
Plasmids 
Please submit copies of your plasmids as DNA or bacterial stocks with Addgene, a non-profit repository, or PlasmID, 
the Plasmid Information Database at Harvard. 
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